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ABSTRACT 
 
The detection and quantification of cancer biomarkers in human blood is crucial to 
diagnose patients in the early stage of a disease. The recent advances in biosensor 
technology can improve detection by reducing the application time and cost without an 
invasive approach. The development of such detection system is a major thrust of the 
rapidly growing biotechnology industry. It involves a multidisciplinary research effort 
including chemical engineering, microelectronics and biology. 
 
This study  focused on the development of nanomaterial-modified sensing platform to 
enhance the sensitivity for cancer marker detection. An electrochemical-based  capacitive 
biosensor was aimed to develop using two alternative nanomaterial modification 
including gold nanoparticles (Au-NPs) and magnetic beads (MBs) in cancer detection for 
the first time. Surface Plasmon resonanse (SPR) and quartz crystal microbalance (QCM)-
based sensors were initially employed to verify the bioassays and the surface chemistries. 
The successful achievement of these research works was transferred into an 
electrochemical based-capacitive biosensor to increase the sensitivity and reliability of the 
assays for the quantification of the biological markers. The optimized sensor methods 
were conducted in the capacitive sensor using standard methodologies and the detection 
limit was increased 6 fold without a signal amplification tool. However, the quantification 
of some biomarkers is difficult since they have trace threshold level in human blood 
and/or small size. Moreover, real patient samples include various biological molecules 
beside the target analyte and this makes the detection difficult due to the non-specific 
responses and requires the signal amplification. Due to these reasons, a novel nanoparticle 
modified capacitive sensor was developed and used for synchronous multiple marker 
detection for the first time. The developed sensor increased the sensitivity up to 600 fold 
(5 pg.mL-1) when compared with standard sensor assays. The results have provided 
alternative and effective quantification approaches to the current tools; and also a 
promising future for precise detection of the cancer types using multiple marker assays. 
The developed and improved methodologies/sensors in this thesis can also be applied for 
the other diseases that have biomarkers in human body. 
 
. 
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ÖZET 
İnsan kanındaki kanser biyomarkırlarının algılanması ve miktarlarının ölçülmesi 
hastalara erken tanı konulması için hayati önem taşımaktadır. Biyosensör teknolojisindeki 
en son gelişmeler invasiv olmayan yöntemlerle, uygulama zamanını ve maliyeti de 
düşürerek tanıyı güçlendirmektedir. Böyle bir teşhis sisteminin geliştirilmesi, hızla 
gelişen biyoteknoloji endüstrisinin bir ihtiyacı olup kimya mühendisliği, mikro elektronik 
ve biyoloji alanlarını kapsayan çok disiplinli bir araştırma gerektirmektedir.  
 
Bu çalışma kanser markır ölçümünde hassasiyeti artırmak amacıyla nanomalzemelerle 
modifiye edilmiş sensör platform geliştirmeye odaklanmıştır. Elektrokimyasal kapasitif 
biyosensör altın nanopartiküller ve magnetik boncuklar olmak üzere iki alternatif 
nanomalzeme kullanılarak geliştirilip kanser markırlarının teşhisinde ilk defa 
kullanılmıştır. Başlangıç olarak, biyolojik metodlar ve yüzey kimyaları  surface plasmon 
rezonans (SPR) ve quartz crystal microbalance (QCM) sensörler kullanılarak 
doğrulanmıştır. Bu araştırmalardan elde edilen başarılı sonuçlar, metodların biyolojik 
markır ölçümündeki hassasiyetini ve güvenilirliğini artırmak amacıyla elektrokimyasal 
temelli kapasitif sensöre transfer edilmiştir. SPR ve QCM’de optimize edilmiş metodlar 
herhangi bir sinyal artırıcı araç kullanmadan kapasitif sensöre uygulandığında markır 
ölçüm hassasiyetinde 6 katlık bir artış elde edilmiştir. Ancak, insan kanındaki bazı 
markırların teşhisi, kanser seviyelerinin iz miktarda oluşu ve/veya boyutlarının küçük 
oluşu nedeniyle zordur. Gerçek hasta örnekleri kanser teşhisinde kullanılacak hedef 
markırın yanısıra çeşitli biyolojik molekülleri içerir ve bu durum spesifik olmayan ölçüm 
sonuçlarına sebep olduğundan biyosensörlerin verdiği sinyal arttırılarak iz miktardaki 
markır seviyelerinin ölçülmesi gerekmektedir. Bu sebeplerle, bu tezde nanopartiküllerle 
modifiye edilmiş yeni bir kapasitif sensör geliştirilmiş ve eş zamanlı-çoklu marker teşhisi 
amacıyla ilk defa kullanılmıştır. Geliştirilen sensor standart kapasitif sensörle 
kıyaslandığında hassasiyeti 600 kata (5 pg. mL-1) kadar arttırmıştır. Elde edilen bulgular 
varolan metodlara alternatif ve etkili ölçüm yöntemleri sunmakta, ve ayrıca çoklu markır 
teşhisi kullanılarak kanser tiplerinin kesin ayrımında ümit vadedici bir gelecek 
oluşturmaktadır. Bu tezde geliştirilen ve iyileştirilen metodlar/ sensörler insan vücudunda 
biyomarkırı olan diğer hastalıkların tanısında da uygulanabilir.  
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CHAPTER 1 
 
 
 
 
1 INTRODUCTION 
1.1 The Need for Cancer Diagnosis 
Cancer is a large group of different diseases that occur due to the unregulated cell 
growth. It may affect people of all ages and certain types of it arises more according to 
the gender, age or geographical location at globe. 13% of all human deaths worldwide 
occurred due to the cancer in 2007. The incidence and mortality rates of the cancer show 
a significant difference depending on the cancer type. For example, the commonest 
cancer types include breast, lung, prostate and colon carcinomas; however, the rate of 
mortality is quite low for breast and prostate cancers when compared with lung cancer. 
Moreover, the mortality and incidence rates of lung cancer show similarity and this 
increases the importance of early diagnosis for the disease. It is the second most common 
cancer in men and the third in women with about 22% of all cancer incidences arise from 
lung cancer (www.cancerresearchuk.org). The disease displays the highest mortality rate, 
1.3 million people per year worldwide, compared to the other common cancers (Figure 
1-1 and Figure 1-2). According to 2005 US statistics 107,416 men and 89,271 women 
were diagnosed with lung cancer, however the vast majority of the patients died from 
lung cancer; 90,139 of men and 69,078 of women ( U.S. Cancer Statistics Working 
Group; Department of Health and Human Services, Centers for Disease Control and 
Prevention, and National Cancer Institute; 2009).   
 
In Turkey the cancer incidence rates  increased between 2002 and 2005 according to 
Ministry of Health Department of Cancer Control database. Incidence rates rose from 
133.78 per 100 thousand in 2002 to 173.85 per 100 thousand in 2005. Lung cancer has 
the highest incidence rate in our country and followed by four other frequent cancer types 
including  prostate (24.33), skin (18.91), breast (17.96), stomach (9.92) cancer with an 
incidence of per 100 thousand as shown in Figure 1-3 [1] . 
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Figure 1-1 The incidence and mortality rates of most common cancers. 
(American Cancer Society, 2008) 
 
 
 
 Figure 1-2 Age-standardised incidence rates in lung cancer, by sex. The x axis shows the 
ages and rate per 100,000 population. (www.cancerresearchuk.org) 
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Figure 1-3 The most frequent ten cancers in Turkey (2005). [1] 
 
 
The treatment of the disease is a long and difficult process and the survival scarcely 
attains to 5 years. The most crucial point for the best result is to diagnose the disease at an 
early stage. For this aim, there are many methods to apply that are chest x-ray, 
computerized tomography, magnetic resonance imaging, positron emission tomography, 
sputum cytology and biopsy although some of them are not suitable to all people due to 
the other pathologies that the patient has (National Cancer Institute). Moreover, the 
patients can often experience a great pain and complication because of some diagnostic 
tools such as biopsy.  
 
Table 1-1 shows the currently available methods for cancer diagnostics with their 
advantages and disadvantages. Since the current diagnostic tools are also time consuming, 
a new sensitive and rapid method is necessary for lung cancer detection. With this 
approach, sensor technology has provided a promising future for the detection of many 
important diseases through rapid, sensitive and easy applications. Getting high specific 
and sensitive results by this technology for the biomarkers from blood samples may 
provide both early and easy detection without painful and non-invasive techniques. 
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Table 1-1: Currently available tools for cancer diagnostics. 
 
Diagnostic method Advantage Disadvantage Reference 
Chest X-ray Quite reliable Use of radiation, false negative 
response, high cost 
[2-3] 
Computerized 
tomography (CT) 
Quite reliable High cost, false negative scans, 
use of radiation 
[4-5] 
Magnetic resonance 
imaging (MRI) 
Quite reliable Use of magnetic field, high cost, 
not suitable for all patients that 
have other complications 
[6-7] 
Pozitron emission 
tomography 
Quite reliable Need for radioactive substance 
and sophisticated instrument, not 
suitable for all patients that have 
other complications, high cost  
[8] [9] 
Sputum cytology Easy and non-
invasive  
Degradation of biomarkers due to 
the enzymes in sputum, false 
positive results 
[10-11] 
Biopsy Fast and easy Inflammation, painful, invasive [12-13] 
 
1.2 Biomarkers for Early Detection of Lung Cancer 
The current blood tests for lung cancer biomarkers base on ELISA type assay and 
gene expression profiling with PCR techniques. Although these methods are promising 
for early detection, they need professional experience, more time and grant. Therefore, 
developing a new technology which provides rapid and highly sensitive detection for 
diseases has been an inevitable aim for scientists. Investigations on biosensors have been 
rapidly increase in last decade to achieve this aim for early, non-invasive and effective 
detection of the important diseases including different kind of cancers, cardiovascular 
diseases and diabetes. There are many protein and genetic markers of lung cancer that can 
be used for detection as seen in Table 1-2 and Table 1-3. 
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 Table 1-2. The list of protein markers of lung cancer  
 
Lung cancer protein marker References 
Neuroendocrine markers, p53 and HER2 [14-15] 
CEA and CYFRA 21-1 [16-17] 
CA 15-3, CA 19-9, TPA [17-18] 
NSE [15, 19] 
TAG-72.3, CA 125, SCC [18] 
hnRNP-A2/B1 [20] 
PCNA and CD34 [21] 
c-erbB2 [22] 
FHIT, CTNNB1, and MUC1 [23] 
Cyclin D1 [24] 
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Table 1-3. The list of genetic markers of lung cancer. 
 
Lung cancer genetic marker References 
P53, FHIT genes [25] 
p19ras gene [26] 
Blood-based CHRNA3 SNP [27] 
Telomere related genes [28] 
miRNAs  [29] 
Bcl-2  [21] 
K-ras [30-32] 
Methylation of p16INK4a [33-34] 
cdc25B gene [35] 
KLF6 gene  [36] 
Polymorphisms in the caspase7 gene [37] 
Polymorfisms in the survivin gene [38] 
p16 gene [39-41] 
KLK5 and KLK7 genes [42] 
Polymorphisms of the RRM1 gene [43] 
RASSF1A and RUNX3 genes [44] 
SEPP1, SEP15 and hGPX1 genes [45] 
Circulating DNA and RNA [46-47] 
 
1.3 Biosensor Technology in Diagnostics 
A biosensor is a device that has two main components including a receptor and a 
detector. The receptor is responsible for the selectivity of the sensor such an enzyme, 
antibodies while the transducer translates the changes that can be chemical or physical by 
recognizing the analyte and relaying it through an electrical signal [48-49]. The detector 
is also called as a transducer that is not selective, for instance it can be an oxygen 
electrode, a pH-electrode or piezoelectric crystal. The biological sensing element 
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selectively recognizes a particular biological molecule through a reaction, specific 
adsorption, or other process as physical/chemical and the transducer converts the results 
of this recognition into a usable signal that can be quantified. Some common biosensor 
materials and various biosystem-transducer combinations take place in Table 1-4 and 
Table 1-5, respectively. 
 
Table 1-4. Some common biosensing materials 
 
                     
                         Analytes 
 
Examples 
 
 
Respiratory gases 
Toxic gases 
Ions 
Metabolites 
Trace metabolites  
Toxic vapors 
Protein and nucleic acids 
Antigen and antibodies 
Microorganism 
 
 
O2,  CO2 
H2S, CI2, CO, NH3 
H+, Li+, K+, Na+, Ca+, phosphates 
Glucose, urea 
Hormones, steroids, drugs 
Benzene, toluene 
DNA, RNA 
Human Ig, anti-human Ig 
Viruses, bacteria, parasites 
 
 
 
Table 1-5. A variety of biosystem-transducer combinations in terms of transducer, 
measurement mode and potential application. 
 
Transducer System Measurement Mode Typical Applications 
 
Ion-selective electrode 
Gas-sensing electrodes 
 
Field-effect transistors 
 
Optoelectronic and fiber -optic 
devices 
Thermistors 
 
Enzyme electrodes 
Conductimeter 
Piezoelectric crystals 
 
 
Potentiometric 
Potentiometric 
 
Potentiometric 
 
Optical 
 
Calorimetric 
 
Amperometric 
Conductance 
Acoustic (mass) 
 
Ions in media, enzyme 
electrodes 
Gases, enzyme, organelle, 
cell or tissue electrodes 
Ions, gases, enzyme 
substrates immunological 
analytes 
pH, enzymes, 
immunological analytes 
Enzyme, organelle, gases, 
pollutants, antibiotics, 
vitamins 
Enzymes, immunological 
systems 
Enzyme substrates 
Volatile gases and vapors, 
antibodies 
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Because of increment of cancer cases in last decade, biosensing technologies have been 
used for cancer detection and the most crucial aim about biosensors is attaining non-
invasive and effective early diagnosis through developing sensor platforms [50]. In this 
project QCM, SPR and IDE-capacitive biosensors were used and developed to investigate 
the biomarkers of lung cancer for early detection. SPR and QCM-based sensors have been 
widely used and reliable tools in biosensing technology. Due to this, these biosensors 
were used for verification of the bioassays and surface chemistries. Electrochemical-
based capacitive sensor was then aimed to use and develop for cancer quantification since 
it provides cost effective, easily applicable and more sensitive measurements in broader 
dynamic ranges of biomarkers. The sensor types employed throughout the thesis were 
briefly mentioned below. 
1.3.1 Optical biosensors 
The basis of optical sensors established on surface plasmon and today the different 
types of the optical sensors are available. These have been investigated and used 
depending on the aim of the studies. The optical biosensors include optrode-based fiber 
optic biosensors, evanescent wave fiber optic biosensors, flow immunosensor, time- 
resolved fluorescence, the resonant mirror optical biosensor, interferometric biosensors 
and surface plasmon resonance biosensors (SPR). 
 
The SPR sensor responds to refractive index near the sensor surface and with binding 
of certain substances such an enzyme to the surface lead to changes in reflectivity (Figure 
1-4). In SPR sensors, a surface plasmon is excited at the interface between a metal film 
and a dielectric medium, changes in the refractive index of are to be measured. A change 
in the refractive index of the dielectric medium (also called as superstrate) produces a 
change in the propagation constant of the surface plasmon. The sensor has been used to 
detect both small analytes as nerve agents and large analytes as a protein [51]. 
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         Figure 1-4 Schematic representation of the SPR detection principle. 
 
1.3.2 Piezoelectric biosensors 
A QCM is a piezoelectric mass-sensing device that measures the change in frequency 
of a quartz crystal resonator as a mass per unit area. In the QCM sensor, analyte detection 
is based on adsorbate recognition where selective binding leads to a mass change that can 
be identified by a corresponding change in the acoustic parameters of piezoelectric quartz 
crystal. With applying electricity to the crystal the piezoelectric effect occurs in crystals 
and the crystal lattice is deformed [52]. In 1959, Sauerbrey firstly demonstrated the basic 
theory of signal dependence on adsorbed mass in which he exhibited that the frequency 
change of a quartz crystal TSM resonator was a linear function of the mass per area ms, or 
absolute mass ∆m: 
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In the formula f0 is the resonance frequency of the unperturbed quartz resonator, Fq the 
frequency constant of the crystal, 𝜌q the quartz density and Ael the electrode area. This 
equation is only valid for thin, solid layers which are deposited on the resonator. After 
Sauerbey, the following studies were done to develop the equation for viscous and lossy 
liquids. Kazanawa, in 1997, expanded the model with this aim and attained the equation 
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below that demonstrates the frequency shift for liquid-loaded sensor surface. Here, the 
liquid is described by its density 𝜌1 and viscosity η1. 
qq
ll
qff µπρ
ηρ2/3−=∆  
 In the formula µq is the shear module in the x-direction and 𝜌𝑞 is the density of the 
crystal. The equations are used as the below representation for a two-layer system: 
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[53] 
Many types of crystals show the piezoelectric effect; however, due to the mechanical, 
electrical and chemical properties of the quartz it is the most commonly used crystal type 
in analytical applications. QCM can be used in a wide variety of applications including 
the detection of small molecular weight ligands, carbohydrates, proteins, nucleic acids, 
viruses, bacteria, cells and lipidic-polymeric interfaces [53]. 
1.3.3 Electrochemical capacitive biosensors 
Capacitive biosensor is a type of electrochemical sensor to detect different kinds of 
molecules including proteins, antigen, DNA, antibody and heavy metal ions. Many 
diseases such as cardiovascular diseases and cancers have been investigated with 
capacitive biosensor to achieve early and simpler diagnosis [54]. The capacitive biosensor 
is an extremely sensitive device that has detection limits under 10-15 molar. Though the 
most commonly studied biosensors are optical ones, the detection limits of the 
electrochemical sensors are anticipated to better with simpler instrumentation that is not 
required the special qualifications for applications [55]. 
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 Figure 1-5 The principle of the bioassay with capacitive biosensor. [55] 
 
The first articles about the applications of the electrochemical sensors for liquids were 
published in late 1980s. In these publications, the principle of the measurement depended 
on the changes in dielectric properties, dimension, shape and charge distribution while 
antibody-antigen complex occurred on the electrode surface. In the event of a 
conformational change of a surface protein through binding of an analyte, this can be 
detected by capacitance measurements. The capacitance measurement can be realized 
through two approaches in an experiment including the measurement of the change in the 
capacitance between two metal conductors in near proximity to one another with the 
recognition element immobilized between them (IDEs) and measuring the capacitance 
potentiostatically at an electrode/solution interface with the recognition components on 
the working electrode surface.  
 
1.4 Use of Biosensors for Lung Cancer Detection and Problems 
Although the disease has available and widely investigated markers as reviewed in 
Table 1-2 and Table 1-3, the lung cancer has scarcely been studied with biosensing technology. 
There are some important limitations related to integration of the disease detection with the use of 
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biosensors. For example, SPR and QCM-based sensors are more common and reliable platforms 
for the aim of biosensing when compared to the other sensor types.  However, these sensors 
require more reagents for the testing and the detection limits are generally high while some 
markers have trace threshold levels for cancer indication such as pg.mL-1 levels. Moreover, the 
parameters have to be optimized for lung cancer markers including surface chemistry, incubation 
type/time for each application during the detection processes. On the other hand, electrochemical 
based-capacitive sensors show a promising approach and compensate the problems of other 
sensor types described above. This platform provides an easier instrumentation without a need for 
special qualifications and cost-effective methodologies although appropriate surface 
modifications, assay optimizations and signal enhancement may be required in many cases. 
1.5 Solutions to Problems and Proposed Study 
Due to the reasons described above, biosensors were investigated/developed to 
provide an alternative/cost-effective and non-invasive approach for the early detection of 
lung cancer that has highest mortality rate because of the limitations on current diagnostic 
tools. With this aim, SPR and QCM biosensors were initially employed to obtain a 
convenient methodology for lung cancer biomarkers. An optimized immunoassay was 
developed for CEA marker detection and this study was published in an international 
journal as one of the first papers in the literature for lung cancer detection using sensor 
technology. In this research, threshold level of CEA marker was successfully detected 
without performing any signal enhancement method. The developed methodology was 
then transferred into an electrochemical based-capacitive sensor platform to reach lower 
detection limits. The detection limit was increased up to 6 fold in capacitive sensor and 
hEGFR marker of lung cancer was successfully investigated. However, the platform was 
required to improve sensitivity since some disease markers have too smaller size and/or 
lower threshold levels to define the occurrence or the stage of the disease. Moreover, 
there is a need for specific immobilization material to detect biological molecules or cells 
by biosensors and the affinity between the immobilization material and the targeted 
marker can be low for many times.  
 
Here, we aimed to improve our capacitive sensor platform to achieve the 
quantification of trace biomarker levels at high specificity using nanomaterials and this 
approach has provided an excellent output when compared with previous investigations. 
The gold and magnetic particle-modified capacitive sensors increased the sensitivity and 
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stability of the sensing platform ~25 fold even for lower concentration of the markers and 
led to 600 fold decrease in the detection limit. 
 
The importance of this work is the development of the nanoparticle modified-
capacitive platforms for the first time and used for lung cancer detection. Here, both Au-
NPs and MBs were successfully implemented to the non-faradaic interdigitated capacitive 
sensor and 600-fold increment was achieved in the detection limit for the tests of lung 
cancer biomarkers. The investigated protein markers during the PhD thesis were seen in 
Table 1-6 with their normal and disease levels. Multiple marker detection for the precise 
detection employing the capacitive sensing platform was the other novelty of this study. 
The improved methodologies and the obtained results provide a very prospective 
alternative approach for the early diagnosis of the cancer cases without an invasive and 
painful tool such as biopsy. The achievements of the study can also be compared with the 
other non-invasive methods including SPR, QCM and capacitive sensors in the literature. 
When we compared our work within itself, it is clear that the particle-modified sensor 
platforms have provided a significant superiority over the other sensors (SPR and QCM) 
and non-modified capacitive sensor platform.  
 
Table 1-6 Summary of disease markers used in this thesis with their normal and disease 
levels. 
Protein Marker Disease Normal 
levels 
Disease 
levels 
Reference 
CEA Cancer 5 ng.ml-1 5 ng.ml-1< [56] 
 
hEGFR Cancer 64 ng.ml-1 64 ng.ml-1> [57] 
 
CA15-3 Cancer 30 U.ml-1 50 U.ml-1< [58] 
 
IL-6 Cancer&CVD 4 pg.ml-1 138 pg.ml-1 [59] 
 
CRP Cancer&CVD 0.22 mg.dml-1 > 1 mg.dl-1 [59] 
 
 
1.6 Organization of the Thesis 
This thesis contains five chapters that explain the assay and surface chemistry 
developments/optimizations with SPR and QCM-based sensors; transferring these 
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methodologies into an electrochemical-based capacitive sensor platform; the development 
of capacitive sensing platform using nanomaterials for signal amplification; multiple 
marker detection using the particle-modified capacitive sensor platforms for the precise 
detection of the cancer cases; and finally conclusions.  
 
A brief outline of each chapter is seen below; 
 
• Chapter 2 describes the assay development and optimizations for the detection of 
lung cancer markers using CEA protein as the model analyte through SPR and 
QCM-based sensors. 
 
• Chapter 3 mentions the successful integration of the developed methodologies in 
SPR and QCM sensors for the electrochemical-based non-faradaic capacitive 
sensor; and the improved sensitivity for the detection of cancer markers using the 
cost-effective and miniature system. 
 
• Chapter 4 presents the nanoparticle modified-capacitive sensor platforms using 
Au-NPs and MBs for more sensitive, reliable and stabile sensing approach; 
comparison of them; and also multiple marker detection for lung cancer cases 
using three different markers of the disease (CEA, hEGFR and CA15-3). 
 
• Chapter 5 gives a summary of the thesis, indicates the novelty and importance of 
the achievements, compares the results of various sensor systems used through the 
thesis with literature and each others, and end up with the future prospects. 
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CHAPTER 2 
 
 
2 CEA MARKER DETECTION THROUGH QCM AND SPR-BASED 
SENSORS 
 
Carcinoembryonic antigen (CEA) has been widely studied in clinical analysis as a 
tumour biomarker. It is a cell adhesion glycoprotein belongs to the immunoglobulin super 
family [60]. The protein was first identified from human colon cancer tissue extracts in 
1965 by Phild Gold and Samuel O. Freedman [61]. It is produced during foetal 
development and the production of it terminates before birth. In healthy individuals the 
normal level of CEA is between 3-5 ng.mL-1 and this level may increase up to 10 ng.mL-1  
due to other benign diseases [62]. The protein scarcely exists in the blood of healthy 
people except cigarette-smokers. However, its concentration shows a significant increase 
in some conditions including lung cancer, colorectal carcinoma, pancreatic carcinoma and 
breast carcinoma [63]. Hence, it can be used as a biomarker for diagnosis and prognosis 
of cancer. CEA levels over 20 ng. mL-1 are usually associated with patients with cancer in 
metastatic state [64]. It is one of the most investigated tumour markers in certain cancers 
[65], with several clinical and research-based applications [16]. However, due to the 
absence of both rapid and sensitive diagnostic tool, CEA related cancers cannot be 
detected at an early stage which is vital for successful treatment. Therefore, biosensor 
technologies can play a crucial role in achieving this aim [50, 66]. Though enzyme-linked 
immunoassay (ELISA) has been generally used for both clinical and research field, the 
QCM or SPR-based biosensors  have provided label-free and real-time detection systems 
[67]. Due to this, the detection of CEA was investigated through QCM (QCMA-1, Sierra 
Sensors) and SPR-based (Biacore 3000, GE Healthcare) biosensor platforms and the 
verified methods were then transferred into the capacitive sensor platform.  
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2.1 Materials and Instrumentation 
Phosphate buffered saline (PBS, 0.01 M phosphate buffer, 0.0027 M potassium 
chloride and 0.137 M sodium chloride, pH 7.4), bovine serum albumin (BSA), N-
hydroxysuccinimide (NHS), 11-mercaptoundecanoic acid (MUDA) and ethanolamine 
were bought from Sigma Aldrich (Poole, UK). 1-ethyl-3-(3dimethylaminopropyl)-
carbodiimide (EDC) was purchased from Pierce-Thermo Scientific (Cramblington, UK). 
Mouse monoclonal antibody to carcino embryonic antigen (CEA) and anti-CEA coated 
with horse radish peroxidase (HRP) were purchased from Abcam (Cambridge, UK). 
Human CEA protein, Mouse IgG and Rat-anti mouse IgG was bought from Stratech 
Scientific Ltd (Newmarket, UK). CEA and its monoclonal antibody were also purchased 
from Sigma (Dorset, UK). QCM-1 and Biacore 3000 biosensors were supplied by Sierra 
Sensors GmbH (Hamburg, Germany) and Biacore GE Healthcare (Uppsala, Sweden), 
respectively. The sensor chips of the QCM-1 and Biacore 3000 were provided by their 
companies.  
 
A fully automated QCMA-1 and Biacore 3000 instruments and their sensor chips 
were selected as the biosensor platforms to develop and detect CEA antigen. QCMA-1 
device has two separate sensing spot whereas Biacore 3000 possess four spots. QCM-1 is 
a kind of piezoelectric mass-sensing device that works by sending an electrical signal 
through a gold-plated quartz crystal which leads to a vibration at some resonant frequency 
and the experiment results are obtained as frequency changes due to alterations in mass 
on the surface of the sensor chip (Figure 2-1). In the assays, one sensing spot of each 
sensor was employed as control surface whilst the others were used as active surfaces. 
The working temperature of the assays was 25 ºC in both sensors and the flow rate was 50 
μl.min-1 and 10 μl.min-1 for QCMA-1 (Figure 2-1) and Biacore 3000 (Figure 2-2), 
respectively. Bare gold sensor chips were cleaned by nitrogen plasma, coated with 
MUDA and then stored in the refrigerator until their use.  
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Figure 2-1. Fully automated QCMA-1 instrument and its sensor chips. 
       
 
Figure 2-2 Biacore 3000 instrument and bare gold sensor chip. 
 
2.2 Sensor Chip Cleaning and SAM Coating 
Used or new chips were cleaned with a procedure including plasma cleaning and 
ethanol washing prior to MUDA coating. The chips were kept in ethanol for some 
minutes, then washed with ethanol and dried with nitrogen stream gently. PC analyser 
(Figure 2-3) was then employed to clean the chip surfaces. There are two different types 
 18 
 
of plasma cleaning with oxygen or nitrogen gasses. For the cleaning of sensor chips 
nitrogen plasma was preferred to employ in this study; however, if bare gold sensor chip 
is previously coated with a polymer or any microorganism detection is studied on the 
surface from the different resources, the O2 plasma should be preferred due to stronger 
nature of oxygen plasma. The setup of the analyser was arranged according to the 
optimised conditions.  
 
 
     Figure 2-3 Emitech K 1050X  plasma asher. (EM Technologies Ltd., Kent, UK) 
 
After plasma cleaning all items were washed with dH2O and ethanol, respectively. The 
chips were kept in ethanol from washing step to preparing MUDA solution. 2 mM 
MUDA was prepared within spectrophotometric grade ethanol for coating the surface of 
sensor chips to form self assembly monolayer (SAM) on the surface. This surface consists 
of the carboxyl group that EDC/NHS can bind to activate carbon groups on the surface. 
The chips were kept in MUDA solution and the petri dish was covered with aluminium 
foil to obtain dark condition during overnight incubation at ambient temperature. MUDA 
coated chips were then washed with ethanol, kept in ethanol for 3 minutes, washed with 
dH2O and dried with N2 stream, respectively. These chips were employed right away or 
kept in refrigerator at +4 °C until their use. 
2.2.1 CEA assay using QCMA-1 sensor 
With docking QCMA-1 sensor chips to the instrument, the assays were started via the 
prime option using previously degassed 1xPBS (Dulbecco’s modified phosphate buffered 
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saline) as running buffer until the immobilisation of antibodies on the surface was 
finished. The chips were then calibrated and a baseline was acquired during 10 minutes to 
understand the situation of the chips before bioassays. To get rid of air bubbles in the 
flow channels was very crucial at this process, because the air bubbles usually cause to 
lose the assay at the beginning of the experiment or misunderstand the result when doing 
analysis due to unexpected signals or drift on the real-time graphs.  
 
Immobilisation stage of the assay was started by injection of 1:1 mixture of 400 mM 
EDC and 100 mM NHS, prepared in deionised water. This solution was immediately 
mixed prior to use and simultaneously injected to the sensor surfaces during 3 min for 
activating the surface. A 30 µg. mL-1 rabbit anti-mouse (RAM) or mouse IgG antibodies 
was then injected to one sensing spot to obtain a control surface whereas same 
concentration of anti-CEA antibody (produced in mouse) was injected to the other spot of 
QCMA-1 device as active sensor surface. Both control and target antibodies were 
prepared in 10 mM sodium acetate buffer (pH 5.5) and injected for 3 min with 50 µl.min-1 
flow rate. The sensor surfaces were then blocked with the injection of a 50 µg.ml-1 BSA 
solution for 3 min that diluted in PBS buffer and finally 1M ethanolamine (pH 8.5) 
injection was employed during 3 min to cap non-reacted NHS esters on the surfaces. The 
produced frequency changes of the sensor surfaces were recorded for immobilised 
antibodies during 2 minutes after the injection of each was completed. After antibody 
immobilisation, the assays were carried on with CEA antigen binding stage. A variety 
concentration of CEA marker was endeavoured to detect. Each concentration of the 
biomarker was injected to the sensor surfaces for 3 min. 
2.3 Results and Discussion for QCMA-1 Assays 
The most important opportunity of QCMA-1 instrument is that it provides a real-time 
experiment approach for users. Due to this, the problems or the tenor of the process may 
be easily understood while the bioassay occurs. The instrument generally has a 
characteristic graph for particular assay types. For QCMA-1 assay, the sensor chips were 
initially coated with MUDA solution to obtain a self assembly monolayer on the surface 
for antibody immobilisation. The coated chip then docked to the sensor, the sensor was 
primed with PBS buffer and 10 minute buffer flow was applied to get a stabile baseline. 
The process was carried on with antibody immobilisation using conventional EDC-NHS 
chemistry.  
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 Rabbit anti-mouse antibody immobilised sensors produced an average frequency 
change of 600 ± 20 Hz (n=3), mouse IgG immobilised sensors produced 727 ± 35 Hz 
(n=3) and anti-CEA immobilised sensors produced 642 ± 40 Hz (n=3) under 25°C 
(Figure 2-4).  
 
 
 
 Figure 2-4. Immobilisation of RAM (blue) and anti-CEA (red) antibodies on the control 
and active sensing spots of QCMA-1 sensor chip at 25 °C. 
 
60 ng.mL-1 CEA was detected by direct assay and the bioassay was repeated for four 
times. Figure 2-5 shows the binding of 60 ng.mL-1 CEA to the active (anti-CEA, red line) 
and control surfaces (mouse IgG, blue line). The sensor surfaces were regenerated with 
100 mM HCI solution after each binding reaction. Sandwich assay was then conducted by 
QCMA-1 sensor; however, the binding between the antigen and the secondary antibody 
could not be observed with standard assay as seen in Figure 2-6. 
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 Figure 2-5 The detection of 60 ng.mL-1 CEA in QCMA-1 device. A 60 ng.mL-1 CEA 
was injected to the active and control surfaces. Anti-CEA provided the active sensor 
surface while mouse IgG was the control. In the graph red line represents CEA binding on 
anti-CEA whereas blue line shows non-specific CEA binding on the control surface 
(mouse IgG). 
 
 
 
Figure 2-6 Sandwich assay with anti-CEA+HRP secondary antibody. First binding shows 
the direct assay using a 40 ng.mL-1 of CEA, the surfaces were then regenerated with 100 
mM HCI. Later sandwich assay was performed with the injection of 20 ng.mL-1 CEA 
marker and a 5 µg.mL-1  of anti-CEA+HRP antibody. The blue line shows the control 
surface whereas the red line is the active sensor surface. 
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To achieve the detection of CEA at lower concentration with higher frequency change, 
detection antibody and CEA antigen were incubated during 2 hours prior to measurement. 
RAM and anti-CEA antibody (Abcam) were immobilised to the sensor surfaces as 
previously described and the incubated samples were then simultaneously injected to the 
surfaces for capture and sandwich assays. The studied concentration range of CEA was 
6.25-400 ng.mL-1 and the amount of detection antibody in the incubated samples was 5 
µg.mL-1. Incubation was performed under ambient temperature on a shaker for 2 hours. 
Capture assay was applied employing RAM immobilised sensor surface whilst sandwich 
assay was performed on anti-CEA immobilised surface. The immobilisation anti-CEA 
antibody was the product of Abcam Company whereas detection anti-CEA antibody from 
Sigma Company. The injection time of each sample was 3 min and the sensor chip 
surface was regenerated after each binding reaction by 100 mM HCI solution. A 5 µg.mL-
1 of the detection antibody was measured as a control prior to CEA included samples and 
30 Hz frequency change was observed between the lowest concentration of CEA sample 
and the control. Figure 2-7 and Figure 2-8 shows the control subtracted data for capture 
and sandwich assays, respectively. As seen in these figures, the produced frequency 
change by the sensor surfaces gradually decreased between 400-50 ng.mL-1 concentration 
of CEA antigen; however, the frequency change shows an increase after this point. This 
was most probably a result of competition between detection antibody and CEA in the 
lower concentration of the antigen for incubated samples and this behaviour was observed 
for both assay types. 
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Figure 2-7. Capture assay results in QCMA-1 instrument in the concentration range of 
400-6.25 ng.mL-1 (from left to right). Each CEA sample included 5µg.mL-1 detection 
antibody. 
 
 
Figure 2-8. Sandwich assay results in QCMA-1 instrument in the concentration range of 
400-6.25 ng.mL-1 (from left to right). Each CEA sample included 5 µg.mL-1 detection 
antibody. The surface was coated by immobilising of anti-CEA primary antibody prior to 
the binding assay. 
 
Here, a QCM-based biosensor was used and the different assay types were conducted. 
CEA marker was tried to detect in a broad dynamic range and the aim was achieved using 
homogenus sandwich and capture assays in the concentration range of 6.25-400 ng.mL-1. 
0
5
10
15
20
25
30
35
400 200 100 50 25 12,5 6,25
Fr
eq
ue
nc
y 
ch
an
ge
 (H
z)
 
Concentration (ng/ml) 
0
4
8
12
16
20
400 200 100 50 25 12,5 6,25
Fr
eq
ue
nc
y 
Ch
an
ge
 (H
z)
 
Concentration (ng/ml)  
 24 
 
However, the sensor assay required further optimization to obtain more stable and reliable 
results according to the concentration of the marker. Due to this, the sensor assays were 
developed in a SPR-based biosensor using CEA marker of lung cancer as model analyte. 
2.4 SPR-BASED IMMUNOSENSOR FOR THE DETECTION OF CEA  
Here, an immunoassay for CEA was developed and optimised on the SPR gold 
sensor surface to achieve high sensitivity for a real-time disease detection.  Different 
homogeneous assay formats were investigated including capture and sandwich 
immunoassays. By using this label-free real-time biosensor a low detection limit for CEA 
which represents the critical CEA level in non-smoker individuals was achieved. The 
detection technique shows a promising future technology for the diagnosis of cancer at 
inchoate stage without the use of invasive surgical procedures.   
2.4.1 Materials and reagents 
Phosphate buffered saline (PBS, 0.01 M phosphate buffer, 0.0027 M potassium 
chloride and 0.137 M sodium chloride, pH 7.4), bovine serum albumin (BSA), N-
hydroxysuccinimide (NHS), ethanolamine, Human CEA (cat no. C4835) and its 
monoclonal antibody (C2331) were purchased from Sigma Aldrich (Poole, UK). 1-ethyl-
3-(3 dimethylaminopropyl)-carbodiimide (EDC) was purchased from Pierce-Thermo 
Scientific (Cramblington, UK). Mouse monoclonal antibody to carcinoembryonic antigen 
(CEA) (cat no. ab10037) and Mouse Monoclonal (1C11) to cardiac Troponin T: ab8295 
was purchased from Abcam (Cambridge, UK), monoclonal PSA detection antibody (cat 
no: MCA2561) obtained from AbD Serotec (Kidlington, UK). Mouse IgG (cat no. 015-
000-003) and rabbit anti-mouse IgG (RAM) was bought from Stratech Scientific 
Ltd./Jackson ImmunoResearch (Newmarket, UK). In the developed sandwich and RAM-
capture assays, Sigma anti-CEA antibody (C2331) was used as the detection antibody to 
perform the assay. All other chemicals were of analytical grade. 
2.4.2 Instrumentations 
A fully automated SPR-based Biacore 3000 biosensor and the bare gold sensor chips 
were supplied by Biacore GE Healthcare (Uppsala, Sweden). The sensor possesses four 
sensing spots that provide four separate areas for different assay simultaneously. In the 
current study two sensing spots were employed for sandwich and indirect assay formats 
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while the third spot provided the control surface. The operating temperature of the assays 
was 25 °C and the flow rate of the buffer was 10 µl.min−1 throughout the assay.  
2.4.3 Sensor chip cleaning and MUDA coating 
Bare gold sensor chips were first cleaned using nitrogen plasma for one minute and 
then coated with self assembled monolayer (SAM) by immersing the sensors in 2 mM 
solution of  11-mercaptoundecanoic acid (MUDA) overnight followed by rinsing with 
ethanol and Milli-Q water and then dried under nitrogen. The SPR sensor chips were then 
stored at 4 oC until used.  
2.4.4  Control surface selection 
For the selection of the best control sensor surface, three different antibodies (mouse 
IgG, anti-PSA and anti-troponin produced in mouse) were examined. Since the samples 
were prepared using 5 µg.mL-1 BSA in all experiments, 300 ng.mL-1 CEA was diluted in 
BSA and the non-specific binding of this solution to each control surface was measured. 
A high concentration of CEA antigen was used in this confirmation study and the non-
specific binding of the antigen to each control surface was recorded during the SPR assay.  
2.4.5 Immobilisation of antibodies 
The SAM coated sensor chip was first docked to the Biacore instrument and primed 
with running buffer (10 mM PBS, pH 7.4, 0.0027 M potassium chloride, 0.137 M sodium 
chloride) at a flow rate of 10  µl.min-1. Monoclonal mouse anti-CEA antibody was then 
immobilised via one flow path of the instrument for the sandwich assay whereas rabbit 
anti-mouse and mouse IgG antibodies (control antibody) were immobilized to the second 
and third sensor array of the chip, to conduct the capture assay and obtain control surface, 
respectively. The immobilisation stage of the immunoassay was obtained using 
conventional amine coupling chemistry. The running buffer in this stage was degassed 
phosphate buffered saline (PBS). During the immobilisation step firstly the sensor chip 
surfaces were activated with a mixture of 400 mM EDC and 100 mM NHS (1:1). Both 
reagents were prepared in deionised water and immediately mixed before use. EDC-NHS 
was injected onto the four sensor surfaces simultaneously for 3 min (30 µl) to activate the 
sensor chip surface. Then, 30 µg.mL-1 coating antibodies (anti-CEA antibodies, rabbit 
anti-mouse and mouse IgG) prepared in 10 mM sodium acetate buffer (pH: 5.5) were 
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immobilized to the sensor surfaces. After antibody immobilisation, the sensor surfaces 
were blocked with 30 µg.mL-1 BSA in PBS buffer for 3 min (30 µl). Finally, 1 M 
ethanolamine (pH: 8.5) was used to cap the non-reacted NHS esters exist on the sensor 
surface for 3 min (30 µl). The RU changes were recorded two minutes after the protein 
injection was completed.  
2.4.6 CEA detection 
First assays were performed using direct assay approach without incubation. To 
increase the signal amplification the homogeneous assay was then applied as sandwich 
and capture methods with an incubation step added before the assay taking place in the 
instrument. Different incubation methods were examined, including water bath at 37 °C 
and with/without shaker at room temperature applied prior to the assay. The CEA and 
detection antibody were incubated in the 1.5 ml Eppendorf tube for each concentration of 
the antigen. The detection antibody concentration was chosen as always higher than CEA 
to prevent any free CEA in the solution that can interfere with the binding results. The 
incubation conditions were then optimized as time, temperature and detection/capture 
antibody concentration. The best results were achieved through applying incubation at 
room temperature for 2 hours using a shaker. PBS buffer was used as the running buffer 
during the CEA marker detection and 5 µg.mL-1 BSA in PBS was used to prepare the 
CEA samples. For the sandwich assay, two different mouse anti-CEA antibodies (a 
coating and detection antibodies) were used while rabbit anti-mouse (RAM) was 
preferred as coating antibody for the capture assay. RAM-capture assay is an indirect 
assay here in which RAM was used to capture either mouse anti-CEA antibody or CEA 
bound mouse anti-CEA antibody. The sensor signal difference due to the mass difference 
of free or antigen (CEA) bound anti-CEA antibody was investigated to obtain the results. 
The anti-CEA captured on RAM causes an SPR signal, however the SPR signal is higher 
(due to higher mass) when antigen bound anti-CEA antibody is captured on RAM 
immobilised surface. By subtracting the two responses the affect of antigen to the assay 
can be calculated. Before samples injection, 5 µg.mL-1 BSA and anti-CEA detection 
antibody were injected to all sensor surfaces as negative controls in the experiments. Each 
CEA sample and negative controls were injected onto the sensor surface for 3 minutes 
and RU changes were recorded. After each binding step the sensor chip surface was 
regenerated by injecting 100 mM HCI (1 min, 10 µl) and additional 20 mM NaOH (1 
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min, 10 µl) where these were found to give the best sensor surface regeneration without 
hindering the affinity of the immobilised antibody. All the data points presented are the 
averages of the triplet measurements unless otherwise stated. The limit of detection 
(LOD) was calculated as the signal obtained from the CEA concentration that is 
equivalent to the 3 times the standard deviation of the signals obtained from the blank 
standards. 
2.5 Results and Discussions 
In this study an SPR based assay for the detection of human CEA tumour marker was 
developed and optimised using different immunoassay formats constructed on the surface 
of a Biacore bare gold sensor chip including a standard capture, rabbit anti-mouse (RAM) 
capture and sandwich assays.  
2.5.1  Assay optimisation 
Bare gold SPR sensor chips were employed in this work as the sensor platform for 
the CEA detection. Each chip consists of four sensing arrays. The modification of the 
chips using self -assembled monolayer’s (SAM) was carried out on the sensor surface. 
The SAM coated sensor chip was first docked to the Biacore instrument and primed with 
running buffer using a flow rate of 10 µl.min-1. To eliminate non-specific binding to the 
control sensor array surface, control surface selection study was conducted. Three 
different antibodies (mouse IgG, anti-PSA and anti-troponin) were investigated and used 
in this study. The antibodies were immobilized to the three different sensor arrays on the 
Biacore chip using different flow channels of the sensor respectively with conventional 
EDC-NHS chemistry [68]. A 3 minutes injection of the antibodies was sufficient to 
achieve the signal with concentration of 30 µg.mL-1 antibody saturation. A 300 ng.mL-1 
CEA solution in PBS buffer containing 5 µg.mL-1 BSA was then injected to all 
immobilised control surfaces on the sensor array. In addition to the CEA, a 5 µg.mL-1 
BSA solution was also examined in a separate experiment in order to measure the non-
specific binding caused by this solution alone. The recorded RU change for non-specific 
BSA binding was 1±1 RU for anti-PSA and anti-troponin immobilized surface while it 
was 1±0.5 for mouse IgG. Moreover, non-specific binding of the CEA antigen against 
each surface was observed at zero level and therefore mouse IgG was selected as the 
control surface for further experiments (Figure 2-9).  
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Figure 2-9 Confirmative assay for the control surface selection with PBS buffer. The non-
specific binding of BSA to each antibody surface (first binding), the non-specific binding 
of CEA antigen in PBS or BSA solution (second and third bindings), the non-specific 
binding of the mixed sample included detection antibody and CEA antigen (last binding). 
The immobilized surfaces: anti-PSA (a), anti-troponin (b), mouse IgG (c).       
 
A standard direct assay format in which the coating anti-CEA antibody was 
immobilized onto the active sensor surface and mouse IgG immobilised to the control 
surface was then developed. CEA antigen was then injected on the sensor surface in the 
concentration range of 100-400 ng.mL-1. Though a clear difference was observed between 
the active sensor surface and the control surface, the obtained results were low despite the 
high concentration of CEA used in the test (Figure 2-10). The recorded response changes 
were 258 ± 19 RU using the standard direct assay for the binding of 300 ng.mL-1 CEA. 
These preliminary tests with high concentrations of CEA showed that the direct detection 
of CEA biomarker using the SPR sensor may not be suitable for the measurement of low 
CEA concentrations. This was confirmed when the optimised direct assay conditions 
were then applied for the detection of lower CEA concentrations (down to 100 ng.mL-1) 
achieving a low and irreproducible signal.  
 
BSA CEA in PBS CEA in BSA Mixed sample in BSA
(a)
(b)
(c)
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Figure 2-10 Direct assay sensorgram with a 300 ng.mL-1  concentration of CEA 
biomarker using the SPR sensor.  CEA antigen binding on Abcam’s anti-CEA 
immobilized (a) and Sigma’s anti-CEA immobilized (b, c, d) sensor surfaces. 
 
Kinetic data analysis was performed for this assay results and the data was fitted to 1:1 
Langmuir binding model to determine the binding association and dissociation rates [69]. 
With this binding model, KA, KD, Rmax values were calculated as 1.13 x 108 M-1s-1, 
8.8 x 10-9M and 215 RU for the concentration of 300 ng.mL-1 CEA (using Abcam 
antibodies in a direct affinity assay) (Table 2-1). Due to the weak responses with the 
direct assay, other assay formats were then investigated. 
 
Table 2-1 Results of kinetic calculations for CEA marker detection with standard and 
optimised assay formats.  
Parameters/Assay 
type 
 
Standard assays Optimised RAM-capture assay 
Optimised 
Sandwich assay 
ka (1/Ms) 
 
8.17 x 104 1x103 6.88 x 105 
kd(1/s) 
 
7.29 x 10-4 1.46 x 10-6 2.09 x 10-5 
Rmax 
 
215 RU 428 RU 734 RU 
KD (M) 
 
8.8 x 10-9 1.46 x 10-9 3.04 x 10-11 
KA (1/M) 
 
1.13 x 108 9.97 x 104 3.29 x 1010 
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A sandwich and RAM-capture assays were then developed under optimised 
conditions that gave much higher response when compared to the standard capture assay. 
Langmuir binding model was also performed for the optimised assays in the linear 
dynamic range of 3-400 ng.mL-1 of CEA and the results are reported in  
 
Table 2-1. The developed assays provided higher responses than the standard direct 
assay format using Rabbit anti-mouse and Abcam anti-CEA antibody as the surface 
capture antibodies and in both assays the anti-CEA antibody (Sigma) was employed as 
the detection antibody. To enhance the sensor signal and improve the sensitivity of the 
assay further an incubation step was introduced where the detection anti-CEA antibody 
(from Sigma) was incubated first with CEA antigen in buffer before the sample was 
applied to the sensor surface. To optimise this step various incubation procedures were 
examined including temperature (37 °C, or 22 °C and with/out shaking conditions). 
Optimal results were achieved when a 22 °C with a shaker incubator was used.  The 
principle of the applied homogenous assays (RAM-capture and sandwich assays) are 
shown in Figure 2-11.  
 
 
Figure 2-11 Schematic representation of homogenous RAM-capture (a) and sandwich 
assay (b). 
 
The concentration of the anti-CEA detection antibody used in the assay was also 
optimised. Various concentrations of detection antibody in the range of 1-5 µg.mL-1 were 
examined using CEA sample concentration range of 50-400 ng.mL-1. Optimal results 
1-hour incubation After incubation The surface of the sensor chip After injection of incubated sample
RAM
CEA antigen
Anti-CEA detection antibody 
Anti-CEA detection antibody
CEA antigen
Anti-CEA coating antibody
(a)
(b)
Antibody immobilisation Antigen detection
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were achieved when 5 µg.mL-1 detection antibody was used. Higher concentrations of 
anti-CEA detection antibody were also tested but did not give higher responses.  The time 
of incubation between the detection antibody and the CEA before injecting on the sensor 
surface was then optimised under these conditions to achieve maximum sensitivity.  The 
RU responses were measured throughout 5 hours and the highest RU changes were 
recorded in the first 2 hours of incubation; however, the obtained RU changes for each 
CEA concentration showed gradual decrease after 2 hours as depicted in Figure 2-12.  
 
Figure 2-12 Optimization of the incubation time. After first 2 hours of the incubation the 
recorded response change was gradually decreased. 
 
However, it must be noted that these samples did not contain preservatives or protein 
stabilisers. After obtaining these results the assays were performed using 1 or 2-hour 
incubation to observe the difference; however, the recorded RU changes were similar in 
both incubation periods. Therefore, 1 hour incubation was preferred to perform the assay 
at ambient temperature on a shaker in order to minimise the total assay time. This 
incubation step was performed prior to the measurement of CEA binding on the Biacore 
3000 biosensor. 
2.5.2  Sandwich and RAM-capture assays characterisation 
In the development of the immunoassay on the sensor chip, three different antibodies 
were used and these included; monoclonal mouse anti-CEA antibody (from Abcam), 
rabbit anti-mouse and mouse IgG. The antibodies were immobilised through the separate 
flow paths of the three arrays on the sensor platform. Anti-CEA monoclonal antibodies 
and rabbit anti-mouse antibodies were used as the coating antibody for the sandwich and 
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RAM-capture assays respectively, whereas mouse IgG provided the control surface. The 
immobilization signal of each antibody was measured during a 3 minutes duration and the 
evaluated RU changes for the immobilization reaction were recorded as 3500 ± 95 for 
anti-CEA (Abcam), 3000 ± 120 for rabbit anti-mouse and 2800 ± 37.6 for mouse IgG 
antibodies respectively (Figure 2-13). A 3 minutes injection of antibodies was sufficient 
for the signal to reach equilibrium; therefore, the immobilisation time was kept at 3 
minutes for the assay. Although the RU changes for the immobilized antibodies showed 
similarity to each other they were different antibodies produced by different companies.  
 
 
Figure 2-13 Immobilisation of anti-CEA coating antibody (red), rabbit anti-mouse (green) 
and mouse IgG (blue) antibodies on the sensor chip surface.  
 
In the sandwich assay method, the CEA antigen in the sample was first incubated with 
the anti-CEA detection antibody (Sigma, 5 µg.mL-1) for 1 hour at 22 oC and then was 
injected on the anti-CEA coated sensor surface. Whereas for the indirect capture assay the 
anti-CEA detection antibody coupled with CEA antigen (Ab-Ag complex) was injected 
on the Rabbit anti Mouse (RAM) and mouse IgG coated sensor arrays for the RAM- 
capture and control assays respectively. Each incubated sample was prepared in 5 µg.mL-
1  BSA and the non-specific binding of both 5 µg.mL-1 anti-CEA detection antibody and 5 
µg.mL-1 BSA were recorded before each experiment. The non-specific binding of 5 
µg.mL-1 anti-CEA detection on the anti-CEA coating antibodies was recorded as 5.1 ± 5.2 
EDC/NHS
Anti-CEA
Ethanolamine
Ethanolamine
Mouse IgG
RAM
BSA
BSA
EDC/NHS
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while non-specific binding of the 5 µg.mL-1 BSA on all surface caused only 3 ± 2 RU 
change.  
 
The selected concentration range of CEA samples for the detection was 3-400 ng.mL-1 
and this concentration range was studied through two different assay types. The recorded 
RU changes were from 30 to 802 RU in the concentration range of 3-400 ng.mL-1 CEA 
and 5 µg.mL-1 detection antibody control caused only 3.5 ± 2.7 RU change in the 
sandwich assay. On the other hand, the obtained results were between 13- 430 RU change 
in the same concentration range of CEA antigen for the RAM- capture assay. Moreover, 
the non-specific binding of CEA on the control surface was measured as only 3.5 ± 2.7 
RU change. Figure 2-14 represents the sensorgrams of the sandwich assays and RAM-
capture assay respectively.  
 
(a)                                                                           (b)                                                  
 
Figure 2-14 Sensorgram of the CEA assay through sandwich (a) and capture (b) methods 
in the concentration range of 3- 400 ng.mL-1. The lowest line represents the control in 
each assay and the RU change gradually increased from bottom to the top according to 
the increased CEA concentration. 
 
A clear difference was observed between the control and active surfaces through both 
assay types. All data were control subtracted. However, the recorded RU changes were 
found to be higher in the sandwich assay (Figure 2-15) when compared to the RAM-
capture assay (Figure 2-16) according to the CEA concentration tested. As it is seen in the 
figures the obtained correlation coefficient of the sandwich and RAM-capture assays 
were 1.00 and 0.99 respectively with the 3 ng.mL-1 detection limit for both assays. 
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 Figure 2-15   The overall results of sandwich assay. (All shown data is control 
subtracted). 
 
 
                                       
 
Figure 2-16 The overall results of RAM-capture assay (All shown data is control 
subtracted). 
 
. Here, we have achieved a detection limit of 3 ng.mL-1 CEA concentration with a 
simple assay design without the use of assay amplifies such as nanoparticles which we 
can implement to enhance the sensitivity further.  The follow up work concentrated on 
transferring/developing the methodologies for an electrochemical-based capacitive sensor 
to reach lower detection limits with a cost effective, miniaturize sensing platform. 
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CHAPTER 3 
 
3 CAPACITIVE SENSOR PLATFORM FOR CANCER DETECTION AND 
QUANTIFICATION 
Capacitive sensors can be divided into two groups as faradaic and non-faradaic 
sensors depending on the transient current flow. In a faradaic process charge is transferred 
across an interface whereas transient currents can flow without addition of a redox charge 
transfer in nonfaradaic processes. Therefore, redox species are alternately oxidized and 
reduced by the transfer of an electron to and from the metal electrode in faradaic 
capacitive sensors. Due to this, these kind of capacitive sensors require the addition of a 
redox-active species and DC bias conditions. On the other hand, additional reagent is not 
required in non-faradaic sensor and this behaviour makes them more amenable to point-
of-care applications [70]. Since we have used non-faradaic capacitive sensors in our 
research group, the main focus was on the development of interdigitated capacitive 
sensors in this PhD thesis. 
 
One of the most crucial points in capacitive biosensors is to immobilize the 
biorecognition layer that has to be sufficiently insulated in order to keep ions on the layer 
to avoid short circuiting of the system that causes a recession or lack of the signal. 
Though different types of semiconductors materials exist, silicon is the most popular one 
to develop capacitive biosensors because of its advantages which are being both 
obtainable under quotable conditions and biocompatible. In the course of an experiment 
the change in capacitance can be measured as a dielectric constant change or the layer 
thickness change immobilized on the transducer.  
 
The principle of the measurement depended on the changes in dielectric properties, 
dimension, shape and charge distribution while antibody-antigen or probe-DNA/RNA 
complexes occurred on the electrode surface. In the event of a conformational change of a 
surface protein through binding of an analyte, this can be detected by capacitance 
measurements. The capacitance measurement can be realized through two approaches in 
an experiment including the measurement of the change in the capacitance between two 
metal conductors in near proximity to one another with the recognition element 
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immobilized between them (IDEs) and measuring the capacitance potentiostatically at an 
electrode/solution interface with the recognition components on the working electrode 
surface. For interdigitated electrodes the capacitance is defined with equation 3.1 
 
𝐶 = 𝜀𝜀0𝐴 𝑑⁄       (Equation 3-1) 
where, ɛ is the dielectric constant of the medium between the plates, ɛ0 (8.85419 Pf/m) is 
the constant of permittivity of free space, A is the area of the plates and d is the distance 
between the plates. According to equation, if a chance occurs in the dielectric properties 
in the supplies between the plates, it leads to a change in the capacitance. The equation 
also shows that the capacitance and its sensitivity increase when the distance of two 
conductors decrease. 
When protein assays are conducted in the capacitive sensor platforms, the antibodies 
have low dielectric constant with respect to water, thus a change in the dielectric 
properties occurs between the electrodes that lead to a variation in the capacitance. 
Interdigitated fingers (Figure 3-1) have been used to obtain a larger sensor surface and 
with some modifications on IDEs they provide the direct detection of many substances 
including acetylcholine, toxin, oxygen bubbles, toxin, HIV and human IgG antibodies. In 
this case, the capacitance between the IDEs can be described by the equation of 
C=2n 𝜀𝜀0A/d where n is the number of electrodes and factor 2 shows each electrode 
forming two capacitors.  
 
Figure 3-1 Schematic representation of the IDEs and parallel plates that mentioned above. 
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Non-faradaic capacitive sensors are also affected by dipole-dipole interactions, 
relaxation time of biological molecules and charge distribution throughout the sensor 
layer. A complex protein includes hydrophobic and hydrophilic regions, and the protein 
folds in a soluble media depending on this behaviour. When the protein fold, the 
hydrophilic regions that include non-polar amino acids constitute the core of the protein 
whereas the polar regions interact with water. There are positively and negatively charged 
amino acids in the protein structure that constitute ionisable side chains. The simplest 
molecular dipole is composed of a pair of opposite electrical charges with magnitude of 
+q and −q and separated by a vector distance (r). The molecular dipole moment (m) is 
defined by the equation m=qr. Each type of polar or polarizable substance displays a 
characteristic response to the imposed electric field. When a protein is immobilized on a 
solid surface and allowed to bind its analyte, a protein–analyte complex is formed. The 
change in conformation brought on by this interaction leads to an increase in molecular 
size of a protein–analyte complex. This increase in size of a protein–analyte complex 
leads to a relatively large permanent dipole moment. The relaxation time and 
polarizability constants can thus be evaluated.  
 
Moreover, proteins have N–C bond in the peptide units that shows a partial double 
bond character and gives a coplanar nature to  CαNHCOCα structure. The C=O bond has 
also polar nature that brings a permanent dipole moment in the peptide bond. Due to the 
permanent dipole moment of each peptide unit in a protein, polypeptide chains take the 
form of strings of connected dipoles. The increase dipole moment directly relates with 
impedance, thus with capacitance. As seen in the following equation, the increased 
diplole moment leads to the decrease in the impedance; therefore, increase in the 
capacitance due to the reverse interaction between the impedance and the capacitance. 
Dipole moment is affected by the charge distrubition of biological molecules, the media 
used and pH. It also relates to polarization. The impedance equivalent network circuit 
bases on Cole-Cole model of IDE sensor. In the equations R∞ is the high frequency 
impedance, R0 is the low frequency impedance, m is the polarizability constant, and τ is 
the relaxation time constant.  
 
𝑍(𝜔) = 𝑍(𝑜){1 −𝑚 �1 − 1
1+(𝑗𝜔𝜏)�}       (Equation 3-2) [71] 
𝑅𝑜 = 𝑍(𝑜)                                                (Equation 3-3) 
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𝑅∞ = 𝑍(𝑜)[1 −𝑚]                                   (Equation 3-4) 
 
In the capacitive sensor platform, the polarizability constant value of only antibody was 
found lower than the antibody-antigen complex. The rotational motion of the target 
antibody-antigen complex can be related to the increase in polarizability constant. The 
dielectric dispersion ∆ε’ = (ε’s – ε’∞) of the antigen injected sample was found higher than 
the control and the changes in the value of ∆ε’ related to change in shape and volume of 
proteins investigated in the study. This may be due to increased conductivity which 
accompanied by a decrease in the values of dielectric constant [71].  
 
The dielectric constants of many liquids and solids depend markedly on the frequency 
of measurement. The dependence is in general found to be a decrease from a static value 
ε0 at low frequencies to a smaller limiting value ε∞  at higher frequencies. In the transition 
region of anomalous dispersion there is an "absorption conductivity" and the situation 
may be described in terms of a complex dielectric constant ε* = ε' - i ε". The classical 
theory of the effect for polar liquids is due to Debye [72]. In this theory the difference 
between the values ε0 and ε∞, is attributed to dipole polarization. The orientation of polar 
molecules in an alternating-current field is opposed by the effects of thermal agitation and 
molecular interactions. Debye represents the second effect by a picture of viscous 
damping, the molecules being regarded as spheres in a continuous medium having the 
macroscopic viscosity. The theoretical analysis in this case leads to equation 3.5. 
 
𝜀∗ − 𝜀∞ = (𝜀0 − 𝜀∞)/(1 + 𝑖𝜔𝜏0)                (Equation 3-5) 
can be written as  
𝜀′ − 𝜀∞ = (𝜀0 − 𝜀∞)/(1 + 𝜔𝜏0)2                 (Equation 3-6) 
 
𝜀′′ = (𝜀0 − 𝜀∞)𝜔𝜏0/[1 + 𝜔𝜏0)2]                    (Equation 3-7) 
 
where 𝜔 = 2π frequency and the parameter  𝜏0 is a characteristic constant which may be 
called the relaxation time. Dispersion and absorption can also occur in nonhomogeneous 
dielectrics. The possibility of absorption in a double-layer dielectric if the ratios of 
conductivities and dielectric constants of the two layers are not equal [73]. Since the 
target antigen–antibody complex has more molecular size than the antibody alone, the 
increase in relaxation time is correlated to the increase in the size of a protein molecule. 
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In this PhD thesis, an electrochemical-based non-faradaic capacitive sensor was 
employed and developed for cancer detection. With this aim, hEGFR marker of lung 
cancer was initally worked without using any signal amplification methods and the 
nanoparticle modified sensor platforms were then conducted to achieve lower detection 
limits with high sentitivity and stability.   
3.1 CAPACITIVE DETECTION OF EGFR  
Human-Epidermal Growth Factor Receptor is a transmembrane glycoprotein, which 
has an extracellular ligand-binding domain and an intracellular domain that possess 
intrinsic tyrosine kinase activity. When a ligand binds to hEGFR, receptor dimerization 
leads to both activation of tyrosine kinase domain and recruitment and phosphorylation of 
intracellular substrates, driving normal cell growth and differentiation. Many molecular 
events may lead to the persistent activation of the kinase activity, consequently triggering 
a broader spectrum of downstream signal transduction pathways. It is documented that 
hEGFR is closely related to cancer and overexpressed in some cancer types including 
lung carcinomas [74-80]. The overexpression of the receptor in various series of non-
small cell lung carcinomas (NSCLC) ranges from 43% to 89%  [81]. The normal range of 
hEGFR in a healthy individual is 64 ng.mL-1 and the level of the marker plays crucial role 
in cancer diagnosis and progression. The lower level of the marker (< 64 ng.mL-1) is 
especially correlated with breast cancer [57], [82-86]. Therefore, the detection of hEGFR 
can play a significant role in early detection of the cancer. 
 
In this work, for the first time, hEGFR was investigated for detection using a GID 
capacitor sensor. A direct detection of hEGFR was demonstrated using hEGFR-antibody 
as the capturing ligand which was covalently immobilized on GID region of capacitors. 
When the immobilized antibody formed a complex with hEGFR-antigen, this interaction 
led to the change in thickness of the dielectric layer on GID surface, and induced changes 
in capacitance that directly related to the antigen concentration. The novelty of this 
research is being (1) label-free method, (2) capacitive detection based on the change in 
surface charges induced by binding of antigen on the antibody immobilized sensor 
surface, and (3) detection of hEGFR marker in real human serum. The method described 
here is based on a direct detection of hEGFR in its native forms without using any signal 
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amplification method or mediator chemicals. Capacitive detection of hEGFR was 
successfully achieved using standard assays in much lower concentration than the normal 
levels (~64 ng.mL-1) and the capacitive sensor was then aimed to develop employing 
nanomaterials for signal amplification in the case of trace biomarker amounts (see 
Chapter 4). 
3.1.1 Material and Methods 
3.1.1.1 Materials and reagents 
Phosphate buffered saline (PBS) and 2X HEPES buffer were purchased from PAN 
BIOTECH GmbH and Fluka, respectively. Ethanolamine (99%), bovine serum albumin 
(BSA), sheep monoclonal antibody to human epidermal growth factor receptor (anti-
hEGFR) and human epidermal growth factor receptor (hEGFR), N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (N-hydroxy-2,5-pyrrolidinedione, NHS) were purchased from Sigma 
Aldrich (USA). HPLC grade 3-Mercaptopropionic acid (MPA, 99%) was purchased from 
Fluka. Human serum was bought from PANTM Biotech GmbH (Germany). Doubly 
distilled water was used throughout the experiments.  
3.1.1.2 Fabrication of the sensor platform 
GID array electrodes were patterned on SiO2 surface using image reversal technique. 
In this process, the metal layers were patterned using the dual tone photoresist AZ5214E. 
A 2-µm thick AZ5214E photo resist was patterned with the help of a mask for a lift-off 
process. Following this step, a very thin titanium layer of ~20 nm size was layered to 
improve the adhesion of gold on the SiO2 film by DC sputter deposition, and about ~180 
nm thick gold layer was deposited. The lift-off process was performed in pure acetone as 
a solvent. The length of each electrode was 800 µm and a width of 40 µm with a distance 
between two electrodes was 40 µm. As a result, each GID array on a capacitor contained 
24 GID fingers. 
3.1.1.3   Sensor chip cleaning and MPA coating 
The fabricated sensor chip was washed several times with ethanol and rinsed with 
sterile dH2O. The cleaned surface was dried by nitrogen gun. The blank measurements 
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were taken by Network Analyzer prior to any surface/bio-chemical treatment/application 
on the surface. The sensor surface was then coated with self-assembled monolayer (SAM) 
by immersing the sensor in 10 mM solution of 3-mercaptopropionic acid (MPA) during 
overnight incubation followed by rinsing with ethanol and Milli-Q water and then dried 
using nitrogen gas. The formation of SAM layer on the surface was confirmed by FT-IR. 
The surface topology, roughness and the distribution of the particles on blank surface was 
observed using an Atomic Force Microscope (AFM, Nanoscope).  
3.1.1.4  Immobilization of antibodies 
The SAM coated GID electrode surface of capacitors were activated using a mixture of 
100 mM EDC and 50 mM NHS (1:1). Both reagents were prepared in sterile-deionised 
water and immediately mixed before the use. EDC-NHS was carefully applied on to each 
GID electrodes in 5 µL volumes and incubated for 4 h in a Petri dish. After the EDC-
NHS activation, the sensor wafer was washed with PBS buffer and then dried with a 
nitrogen gun. Each GID capacitor was immobilized by incubating 2.5 µL of 50 µg.mL-1 
anti-hEGFR antibody in PBS buffer for 1 h. (To determine the optimal antibody 
concentration in our sensor platform, a preliminary test was performed using different 
concentrations of the antibody and 50  µg.mL-1  was then selected according to the 
results.) The sensor wafer was then washed with PBS and dried prior to the blocking step 
with ethanolamine. The non-reacted groups on the sensor surface were blocked by adding 
5 µL of 100 mM ethanolamine on each GID electrode and incubated for 2 h. The 
antibody immobilized sensors were further subjected to blocking with 2.5 µL of 50 
µg.mL-1 bovine serum albumin (BSA). The sensor was then rinsed with PBS and sterile 
dH2O, and dried with nitrogen gun prior to the measurements for antibody immobilization 
using a Network Analyzer. The analyzer was calibrated and triplicate measurements were 
then taken for each GID electrode for error analysis. FT-IR of the antibody immobilized 
surface was performed for confirmation and AFM images were taken to compare with 
blank surface. 
3.1.1.5  hEGFR protein detection 
A series of hEGFR concentrations (0.5-256 ng.mL-1) were prepared in 1X HEPES 
buffer and the same buffer was used as a blank control. Each concentration of the 
biomarker was tested on three independent GID capacitors for error analysis. The hEGFR 
 42 
 
samples prepared in the buffer were incubated for 2 h for the antigen detection step and 
the sensor was then carefully rinsed with PBS followed by dH2O to remove traces of salts 
on the sensor surface. The sensor was quickly dried with nitrogen gas and each GID 
capacitor was measured for the detection of hEGFR marker.  The specificity of the 
interaction between the target antibody (anti-hEGFR) and antigen (hEGFR) was checked 
by applying 50 ng.mL-1 of non-specific BSA protein on the anti-hEGFR immobilized 
(GID) electrodes instead of the target protein marker. The average values of the change in 
capacitance were plotted and the standard deviations of the triplicate experiments were 
shown as error bars. 
3.1.1.6  Detection of hEGFR in human serum sample  
The human serum sample was spiked with different concentrations of hEGFR protein 
(0-10 ng.mL-1). The hEGFR concentrations were prepared in 100% human serum (Type 
AB, Male donar, PANTM Biotech GmbH). For negative control, BSA protein was spiked 
in human serum in a final concentration of 50 ng.mL-1 and incubated on the antibody 
immobilized surface to validate the specificity of the binding between target antibody-
antigen pair. All samples were incubated on the sensor surface for 2 h. After the antigen 
binding process during 2 h, the sensors were washed for three times with PBS buffer 
followed by quick wash with distilled water to remove traces of salt and other molecules. 
Finally, the sensor was dried before taking the measurements. Each concentration of the 
marker was incubated on three independent GID capacitors for error analysis and the 
measurements were taken using a Network Analyzer.  
3.1.2 Results and Discussions 
In this study, we report on a bioassay using an electrochemical-based capacitive 
sensor platform for the detection of hEGFR, whose level is a potential indicator to assess 
whether a patient is at a risk of breast or lung cancers. Although hEGFR receptor has a 
crucial importance for the diagnosis of cancer, both investigations and applications have 
been limited with current diagnostic and monitoring techniques that are time-consuming, 
invasive or require high-cost. To our knowledge, EGFR has been not investigated with 
sensor technologies yet. There is only one published study that mentioned the anti-EGFR 
antibody modification with colloidal gold nanoparticles to detect the living whole cells. 
The researchers used surface plasmon resonance (SPR) scattering technique to measure 
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the cell viability that is completely different approach when compared with our work 
[87]. Aaron et al. applied the similar methodology with various nanoparticles and optical 
imaging to measure the cell viability using EGFR [88]. Choi et al. performed ELISA test 
to detect hEGFR for gastritic carcinoma patients and could measure 0.6 nmol of EGFR 
[89]. When we compared the detection limit of ELISA with our test we could achieve to 
detect 2.94 fmol that is much lower with respect to the ELISA test. (0.5 ng.mL-1 was 
converted to the mole to do exact comparison and it is equal to 2.94 fmol for 170 kDa 
protein). Moreover, the ELISA technique does not provide higher sensitivity and it needs 
much more reagent with special qualifications. 
Here, a real time, label-free and non-invasive method was adapted through a highly 
sensitive and specific capacitive sensor array to detect the cancer marker hEGFR for the 
first time (Figure 3-2).  
 
 
Figure 3-2 Microscopic image of gold interdigitated transducer electrode array. 
3.1.2.1  FT-IR analysis of SAM-coated and EDC-NHS activated GID surfaces 
The fabricated sensor platform was subjected to SAM formation with 3-
Mercaptopropionic acid. The SAM coated sensor surface was then activated with an 
EDC-NHS mixture prior to the immobilization of anti-EGFR antibody. The activated 
sensor surface was scanned and the recorded FT-IR spectra were compared with the 
reference spectra [90] and all spectra were collected with 64 scans for the reference and 
the sample, with 4 cm-1 resolution in the reflection mode. FT-IR spectrum of SAM coated 
surface indicated the formation of a MPA layer on the gold surface by the disappearance 
of the S-H stretch at 2551.5 cm-1, as well as the existence of CH2 vibration (at 780 cm-1) 
GID electrodes
Interdigitaded fingers insight
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and C-C stretch (~1150 cm-1) that is present in MPA backbone [91] (Figure 3-3a). FT-IR 
spectra of the sensor after EDC-NHS application verified the activation of the surface 
through the additional bond on the spectra, representing the ester chemical group. The 
ester bound belonged to the NHS complex and it is expected between 1500-1700 cm-1 as 
in our FT-IR spectra (at 1698.15 cm-1) [92]. The Si-O stretch in 1000 cm-1 peak came 
from the fabricated capacitive sensor, as gold was patterned on silicon dioxide wafer 
(Figure 3-3b).  
a) 
 
b) 
 
Figure 3-3 FT-IR spectra of SAM coated (a) and EDC-NHS activated (b) sensor surfaces. 
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Different concentrations of anti-hEGFR antibody were initially tested for 
immobilization and 50 µg.mL-1 antibody concentration was determined as the optimum 
concentration for this study. Anti-hEGFR antibody (50 µg.mL-1 in a 2.5 µL volume) was 
immobilized on to each EDC-NHS activated capacitor sensor surface for 1 h and the non-
reacted groups were blocked with ethanolamine, and later by BSA as a non-specific 
protein to prevent from any non-specific binding on the surface during the antigen 
detection steps.  
3.1.2.2 Surface topology by atomic force microscopy (AFM) of the sensor surface 
To confirm the antibody immobilization on the electrodes, the surface characterization 
was performed using tapping mode AFM [93].  The surface topographical AFM image of 
electrodes for blank and antibody immobilized surfaces were shown in Figure 3-4. AFM 
height image (Figure 3-4a and b) and the distance between the particles (Figure 3-4c and 
d) on blank and antibody immobilized surfaces were compared. When the distribution of 
the particles on the blank and immobilized surfaces were considered, the distance 
between two particles were determined to be ~100 nm and ~175 nm, respectively. This 
difference could be attributed to the existence of different size molecules on the 
immobilized surface [71].  3D-height map image of the blank and the immobilized 
surfaces showed varying heights within scanned 11 µm2 electrode area. The surface 
roughness was measured as 345.9 nm.µm-1 and 486.0 nm.µm-1 for blank and antibody 
immobilized surfaces, respectively (Figure 3-4e and f). The increase on the surface 
roughness confirmed the immobilization of the antibody when compared to the blank 
surface [71]. 
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Figure 3-4 AFM analysis of blank and antibody immobilized surfaces. Height images (a, 
b), particle distribution on the surface (c, d) and surface roughness (e, f) of blank and 
antibody immobilized sensor platforms. 
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3.1.2.3 Determination of hEGFR using Network Analyzer 
The sensor surfaces immobilized with anti-hEGFR antibodies were used for the 
determination of hEGFR antigens. For this, a Network Analyzer was employed to record 
the S11 parameters generated due to the immobilization of anti-hEGFR antibody on each 
GID capacitor. For the analysis, the capacitance was deduced from the S11 parameters. 
First, different concentrations of hEGFR antigen (0.5-256 ng.mL-1) in a final 2.5 µl 
volume were incubated on each GID sensor surface in triplicates and bovine serum 
albumin (BSA, 50 ng.mL-1) was used as a negative control. The specificity of the sensor 
to hEGFR was derived from the specific binding between the anti-hEGFR and hEGFR 
antigen as there was no binding with BSA non-specific protein. To observe the baseline 
response of the dilution buffer, 1 HEPES buffer (no antigen) was also incubated on 
three GID electrodes as the blank control. The sensor platform was scanned in the 
frequency range of 50 MHz-1 GHz and inter-assay analysis was performed with three 
independent experiments. The deduced capacitance after antigen binding was subtracted 
from the values obtained for only antibody immobilization and the results were analysed 
as the normalized capacitance change (∆C) according to the equation 3-8. 
 Normalized ∆C = CAntigen−CAntibody
CAntibody
         Equation 3-8 
 
A clear difference and the sensitivity in response to hEGFR antigen were evident 
under the applied frequency. The clear difference in sensor response with target antigen 
was probably dependent on the nature of protein and geometry of metal electrodes [94-
95]. For the frequency range analysed, the antigen was clearly detected in the 
concentration range of 0.5-64 ng.mL-1. Further, no response with BSA or with blank 
(1HEPES buffer) indicates the specificity of the bioassay (Figure 3-5). The logarithmic 
regression analysis with responses obtained at 800 MHz frequency was chosen that 
exhibited the dynamic detection range of 0.5-64 ng.mL-1 with good correlation (R2=0.97) 
as shown in Figure 3-6. The saturation level of the immunoassay was achieved at 64 
ng.mL-1 hEGFR concentration. 
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Figure 3-5 Changes in the capacitance depending on the different concentrations of 
hEGFR antigen in the frequency range of 700-850 MHz. 
 
 
Figure 3-6 Logarithmic regression and correlation coefficient of the results obtained at 
800 MHz frequency. 
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3.1.2.4 Kinetics of hEGFR binding on the sensor surface 
The responses obtained at three different frequency points did not affect the capacitive 
signal significantly and a consistency was observed according to the concentrations tested 
in buffer conditions (Figure 3-7). The affinity of the anti-hEGFR antibody immobilized 
sensor surface against to hEGFR was calculated by assuming the Langmuir adsorption 
isotherm and the data fitted to non-linear regression analysis, and the dissociation 
constants (Kd) was determined [56, 96]. 
 
Figure 3-7 Kinetic analysis for the bioassay in dose and frequency dependent manner. 
 
 The Kd was calculated from the tested concentration range of 0.5-64 ng.mL-1. The 
maximum responses at frequencies of 700, 750 and 800 MHz were calculated and the 
dissociation constants were found to be consistent to their capacitive signal with Kd 
values of 6.05, 5.6 and 5.7 ng.mL-1, respectively (Table 3-1). These Kd values indicated 
the strong binding nanogram levels of hEGFR occurred in buffer, against a constant 
number of anti-hEGFR antibodies present on an area of 33 mm2 with a defined 
geometry of sensor surface, under standard condition as described in experimental 
methods. 
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Table 3-1 Calculations of dissociation constants (Kd) and maximum responses (Rmax) in 
the selected frequency points in the concentration range of 0.5-64 ng.mL-1 antigen. 
 
Frequency (MHz) Max. response (Rmax) (pF) Dissociation constant (\Kd) (ng mL-1) 
700 1.139 6.05  
750 1.272 5.65  
800 1.354 5.69  
 
3.1.2.5 Detection of hEGFR in real human serum samples 
It was imperative to test the sensor platform for hEGFR detection in a complex real 
human serum to evaluate the potential applicability of the sensor assay for suspected 
serum samples. Therefore, different concentrations of hEGFR protein (0-10 ng.mL-1) 
were spiked in real human serum. The sensor containing constant number of immobilized 
anti-hEGFR antibodies was incubated with serum containing different concentrations of 
hEGFR. The sensor showed sensitive capacitance responses to hEGFR with an 
extrapolated linear detection limit of 0.5-10 ng.mL-1 in human serum (Figure 3-8). 
Normal serum samples without target marker spiked were used as the negative control. 
The capacitance response of the control showed only negligible background signal. This 
was probably because of washing the sensor surface with PBS buffer after incubating 
with serum, followed by blocking free and active functional groups and passivation by 
coating with BSA. Here, the sensor surface was normally dried before taking each 
capacitance measurement that may have also contributed to prevent large background 
signal. Therefore, we observed no interference of other serum molecules on the sensor 
surface, enabled measuring signal that was indeed coming from the binding of hEGFR on 
the sensor surface.  
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Figure 3-8 Test of hEGFR protein in real human serum in the concentration range of 0-10 
ng.mL-1. 
 
The results demonstrated that use of GID capacitors has a great potential for early 
detection of the cancer and it is also a promising alternative platform where rapid 
detection, early diagnosis, lower cost are higher priorities. When compared with other 
sensor platforms (optical, piezoelectric, electrochemical sensors), the capacitive biosensor 
has provided a simpler instrumentation, possibility of miniaturization for point of care 
application, extreme sensitivity and less expensive that do not require qualified personnel 
to use the sensor. The miniaturization could provide usage of very little amount of sample 
and the nano-patterning of gold interdigitated fingers of capacitors would further increase 
the surface, and thus, increase the sensitivity of the recorded signal for biomarker 
detection. 
 Although the sensitivity of the sensor is good, it needs further improvement to detect 
the markers that have threshold levels at pg.mL-1 and extent the dynamic concentration 
range for the detection. With this aim, the capacitive sensor was developed using 
magnetic and gold particles with different methodologies for signal amplification 
(Chapter 4). 
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CHAPTER 4 
 
 
4 DEVELOPMENT OF NANOPARTICLE-MODIFIED CAPACITIVE SENSOR 
PLATFORM 
The SPR and QCM-based sensors were employed for the verification of the 
bioassays/surface chemistries and the methods were then transferred into an 
electrochemical-based capacitive sensing platform to enhance sensitivity while decrease 
the cost and the need for special qualification on the use of sensor. We initially tested this 
biosensor with standard methods and then we aimed to develop it using gold and 
magnetic particles for signal amplification. These nanoparticles were employed through 
performing different methodologies. In the section 4.1, Au-NP modified platform was 
described and the signal was increased via the enhancement of the surface for the binding 
of biological molecules. For this, the capacitive sensor platform was initially covered with 
a SAM layer and then modified with Au-NPs prior to the antibody immobilization. On 
the other hand, (section 4.2), magnetic beads were used for signal amplification at the end 
of the bioassays. For this, the appropriate magnetic bead amount and the frequency range 
for the marker quantification were determined. Magnetic beads were functionalized with 
a detector antibody using a specific method. The sensor was initially immobilized with 
surface antibody and then treated with target marker. The functionalized beads were 
injected to the sensor after antigen binding to improve the signal. This led to detect trace 
concentrations of the markers which could not be detected without using magnetic bead 
modification.  
4.1 GOLD NANOPARTICLE MODIFIED SENSOR PLATFORM 
Electrochemical biosensors created by coupling biological recognition elements with 
electrochemical transducers based on or modified with gold nanoparticles have played an 
increasingly important role in biosensor research over the last few years. The great 
promise of these bioelectroanalytical devices derive from the unique properties of gold 
nanoparticles [97-98]. Among them, their ability to provide a stable surface for the 
immobilization of biomolecules that retain their biological activities (probably due to 
enhanced orientational freedom) is extremely useful when preparing biosensors. 
Moreover, gold nanoparticles permit direct electron transfer between redox proteins and 
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bulk electrode materials, which allows electrochemical sensing to be performed without 
the need for electron-transfer mediators. Various characteristics of gold nanoparticles, 
such as their high surface-to-volume ratio, their high surface energy, their ability to 
decrease the distance between proteins and metal particles, and their ability to act as an 
electron-conducting pathway between prosthetic groups and the electrode surface, may 
facilitate electron transfer between redox proteins and the electrode surface [98]. 
 
Gold nanoparticle-modified electrode surfaces can be prepared in three ways: (a) by 
binding gold nanoparticles with functional groups of self-assembled monolayers (SAMs); 
(b) by direct deposition of nanoparticles onto the bulk electrode surface; (c) by 
incorporating colloidal gold into the electrode by mixing the gold with the other 
components in the composite electrode matrix. Biosensors can then be constructed by 
immobilizing the biomolecules by adsorbing them onto the nanoparticles, by cross-
linking them with bifunctional agents such as glutaraldehyde, or by mixing them with the 
other components of composite electrodes [99]. In this work, the interdigidated capacitive 
transducer was modified with Au-NPs after SAM formation for signal amplification to 
detect trace amount of cancer biomarkers (Figure 4-1). This method allowed us to prevent 
from negative background signal that plays crucial role especially for the detection of 
serum or real patient samples. Thus, too small or low level of biomarker can be 
specifically detected in human body fluids without time-consuming, high-cost 
methodology.  
 
 
Figure 4-1 The principle of the bioassay on Au-NP modified capacitive sensing platform. 
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4.1.1 Materials and Methods 
Phosphate buffered saline (PBS) and 2X HEPES buffer were purchased from PAN 
BIOTECH GmbH and Fluka, respectively. Ethanolamine (99%), bovine serum albumin 
(BSA), mouse monoclonal antibody to human IL-6, human IL-6 antigen, thiourea, N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) and N-
hydroxysuccinimide (N-hydroxy-2,5-pyrrolidinedione, NHS), sheep monoclonal antibody 
to human epidermal growth factor receptor (anti-hEGFR) and human epidermal growth 
factor receptor (hEGFR) were purchased from Sigma Aldrich (USA). CEA and CA15-3 
antigens and their monoclonal antibodies were bought from Fitzgerald (USA). Gold 
nanoparticles were purchased from NanoComposix (San Diego, CA). Doubly distilled 
water was used throughout the experiments.  
4.1.1.1 Preparation of Au-NP modified sensor platform 
Gold interdigitated electrodes were fabricated and cleaned prior to do any application 
as described in section 3.1.1.2. The fabricated sensor chip was washed several times with 
ethanol and rinsed with sterile dH2O. The cleaned surface was dried by nitrogen gun. The 
blank measurements were taken by Network Analyzer prior to any surface/bio-chemical 
treatment/application on the surface. The sensor surface was then coated with self-
assembled monolayer (SAM) by immersing the sensor in 10 mM solution of thiourea 
which has two amine group during overnight incubation followed by rinsing with ethanol 
and Milli-Q water and then dried using nitrogen gas. The formation of SAM layer on the 
surface was confirmed by FT-IR. Au-NPs that have 5-nm size was prepared using the 
buffer solution in 27 µg.mL-1  concentration [100]. Au-NPs were then applied onto the 
GID electrodes for 8 hours to enhance the immobilization surface of the antibodies. The 
sensor platform was then washed with PBS and dH2O. The capacitive response of Au-NP 
application was measured employing a Network Analyzer. To confirm the modification 
of the platform using Au-NPs; the surface topology, roughness and the distribution of the 
particles on Au-NP modified surface was tested through an Atomic Force Microscope 
(AFM, Nanoscope) and compared with non-modified surface.  
4.1.1.2 Antibody immobilization 
The Au-NP modified GID electrode surfaces of capacitors were immobilized by 
incubating 2.5 µL of 25 µg.mL-1 IL-6 antibody in PBS buffer for 1 h. The sensor wafer 
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was then washed with PBS and dried prior to the blocking step with ethanolamine. The 
non-reacted groups on the sensor surface were blocked by adding 5 µL of 100 mM 
ethanolamine on each GID electrode and incubated for 1 h. The sensor was then rinsed 
with PBS and sterile dH2O, and dried with nitrogen gun prior to the measurements for 
antibody immobilization using a Network Analyzer. The analyzer was calibrated and 
triplicate measurements were then taken for each GID electrode for error analysis.  
4.1.1.3  Protein detection 
A series of IL-6 concentrations (0.02-10 ng.mL-1) were prepared in 1X PBS buffer 
and the same buffer was used as a blank control. Each concentration of the biomarker was 
tested on three independent GID capacitors for error analysis. The IL-6 samples prepared 
in the buffer were incubated for 1 h for the antigen detection step and the sensor was then 
carefully rinsed with PBS followed by dH2O to remove traces of salts on the sensor 
surface. The sensor was quickly dried with nitrogen gas and each GID capacitor was 
measured for the detection of IL-6 marker.  The specificity of the interaction between the 
target antibody (anti-IL6) and antigen (IL-6) was checked by applying 10 ng.mL-1 of non-
specific BSA protein on the anti-IL6 immobilized (GID) electrodes instead of the target 
protein marker. The average values of the change in capacitance were plotted and the 
standard deviations of the triplicate experiments were shown as error bars. 
4.1.2 Results and Discussions 
4.1.2.1 FT-IR and AFM analysis 
The fabricated sensor platform was subjected to SAM formation with thiourea. Since 
thiourea was used for the first time by our research group, self assembled monolayer of 
thiourea was tested using FT-IR. The sensor surface was scanned and the recorded FT-IR 
spectra were compared with the reference spectra [90] and all spectra were collected with 
64 scans for the reference and the sample, with 4 cm-1 resolution in the reflection mode. 
FT-IR spectrum of SAM coated surface indicated the formation of a thiourea layer on the 
gold surface by the disappearance of the S-H stretch at 2551.5 cm-1, as well as the 
existence of NH vibration (at 779 cm-1) and CH stretch (at 1150 cm-1) [91]. The Si-O 
stretch in 1000 cm-1 peak came from the fabricated capacitive sensor, as gold was 
patterned on silicon dioxide wafer (Figure 4-2).  
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Figure 4-2 Confirmation of SAM formation with thiourea employing FT-IR prior to Au-
NP modification. 
 
To verify the modification of the capacitive transducer with Au-NPs, AFM was 
employed and height images, particle distrubition on the surface were compared for Au-
NP modified and non-modified sensor paltforms. Attachment of Au-NPs on the surface 
verified the modification as seen in Figure 4-3. Surface roughness was observed as 
509.61 nm.µm-1 for Au-NP modified sensor  while it was recorded as 244 nm.µm-1 for 
non-modified sensor surface (Figure 4-3a and b). When the distribution of the particles 
on the Au-NP modified and non-modified sensor surfaces were considered, the distance 
between two particles were determined to be ~50 nm and ~150 nm, respectively. This 
difference was attributed to the existence of Au-NPs on the surfaces that increase the 
surface and capture more biological molecule when compared with non-modified surface 
(Figure 4-3c and d). This may be due to their ability to provide a stable surface for the 
immobilization of biomolecules that retain their biological activities (probably due to 
enhanced orientational freedom) is extremely useful when preparing biosensors. 
Moreover, various characteristics of gold nanoparticles, such as their high surface-to-
volume ratio, their high surface energy, their ability to decrease the distance between 
proteins and metal particles, and their ability to act as an electron-conducting pathway 
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between prosthetic groups and the electrode surface, may facilitate the binding of more 
antibody [101]. 
 
 
Figure 4-3 Confirmation of Au-NP modification on the sensor using AFM tool. Surface 
roughness of Au-NP modified (a) and non-modified (b) sensor platforms. Particle 
distribution on the Au-NP modified (c) and non-modified (d) sensor surfaces. (Red 
arrows show the distance between two particles). 
4.1.2.2 Determination of IL-6 antigen  
A Network Analyzer was employed to record the S11 parameters generated due to the 
SAM formation, Au-NP application and the detection of IL-6 antigen using IL-6 antibody 
on each GID capacitor. For the analysis, the capacitance was deduced from the S11 
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parameters. Capacitive response of SAM formation and Au-NP application were initially 
measured by Network Analyzer and validated for 5 separate electrodes. To prevent from a 
background capacitance prior to the antigen detection, it was expected that Au-NPs would 
not increase the capacitance. The comparison of the capacitive responses of SAM and 
Au-NP applications shows that Au-NP changed the dielectric permittivity and charge 
distribution of the medium and leads to a little decrease on capacitance prior to the 
antibody immobilization (Figure 4-4). The difference between capacitive response of 
SAM and Au-NP according to the IDTs was observed ~0.06 pF. 
 
 
Figure 4-4 Capacitive responses of SAM-coated and Au-NP modified sensor surfaces for 
5 electrode. 
 
After Au-NP modification, 25 µg.mL-1 was immobilized to the sensor surface for the 
detection of IL-6 antigen. Different concentrations of IL-6 antigen (0.02-10 ng.mL-1) in a 
final 2.5 µl volume were incubated on each GID sensor surface in triplicates and PBS 
buffer was used as a negative control. The optimal antibody concentration for the 
immobilization changes between 20-50 µg.mL-1 in different biosensor types. The various 
concentrations between this range for antibody immobilization were tested throughout the 
PhD thesis using SPR, QCM and capacitive sensor platforms. A preliminary test was also 
performed prior to this study and a 25 µg.mL-1 antibody concentration was chosen. The 
investigated antigen concentration was selected between 0.02 ng.mL-1 and 10 ng.mL-1 
since we could detect 0.1-10 ng.mL-1 concentration of IL-6 using standard assay 
methodology in our previous works. The Au-NP modified sensor platform was initially 
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tested using IL-6 in the selected concentration range and the sensitivity level was then 
increased with lower concentrations according to the results obtained here. 
 
The specificity of the sensor to IL-6 was derived from the specific binding between 
the anti-IL6 and IL-6 antigen as there was no binding with BSA non-specific protein. The 
sensor platform was scanned in the frequency range of 50 MHz-1 GHz and inter-assay 
analysis was performed with three independent experiments. The deduced capacitance 
after antigen binding was subtracted from the values obtained for only antibody 
immobilization and the results were analysed as the normalized capacitance change (∆C). 
The normalized capacitance was calculated according to the equation 3.8. A clear 
difference and the sensitivity in response to IL-6 antigen were evident under the applied 
frequency. For the frequency range analysed, the antigen was clearly detected in the 
concentration range of 0.02-10 ng.mL-1(Figure 4-5).  
600 700 800 900 1000 1100
1,4
1,5
1,6
1,7
1,8
1,9
2,0
No
rm
al
ize
d 
∆C
 (p
F)
Frequency (MHz)
 10 ng/ml
 5 ng/ml
 1 ng/ml
 0.1 ng/ml
 0.05 ng/ml
 0.02 ng/ml
 0 ng/ml
 
 
Figure 4-5 Capacitive detection of IL-6 marker with standard errors in the frequency 
range of 600-1000 MHz. 
 
To determine the optimal frequency range of bioassay with Au-NPs, 6 frequency points 
between 600-1000 MHz were selected and validated and the capacitive response showed 
saturation after 800 MHz frequency point as seen in Figure 4-6. It was observed that 
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frequency range was fitted with our normal range for biological assays in the platform 
since the best results were usually obtained between the range of 600-850 MHz. 
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Figure 4-6 All investigated concentration range of IL-6 at selected 6 frequency points to 
determine the optimal frequency range for the bioassay. 
   
Further, a constant frequency was chosen and the logarithmic regression analysis was 
performed in the dynamic detection range of 0.02-10 ng.mL-1 with good correlation 
(R2=0.98) as shown in Figure 4-7.  Kinetic data analysis was also performed in the 
selected frequency points to determine the binding affinity between target antibody-
antigen pair on the Au-NP modified sensor platform. Table 4-1 shows the dissociation 
constants (Kd) at particular frequencies with standard deviations.  
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Figure 4-7 Logarithmic regression analysis for the bioassay at a constant frequency point 
(800 MHz). 
 
 
Table 4-1 Kinetic data analysis at selected frequency points to determine the affinity 
between the target antigen-antibody pair (IL-6-anti-IL-6). 
 
Frequency (MHz) Dissociation constant (\Kd)(ng. ml-1) Std error 
800 1.60 ± 0.2 
850 1.59 ± 0.1 
900 1.50 ± 0.4 
950 1.58 ± 0.3 
1000 1.59 ± 0.1 
 
We previously investigated IL-6 marker using standard assay methodology in the 
concentration range of 0.1-10 ng.mL-1 and the obtained signal was much lower than the 
Au-NP modified sensor surfaces. The 10 ng.mL-1 concentration of IL-6 gave ~0.35 pF 
and ~2 pF response with standard and modified sensor platforms, respectively. Moreover, 
0.02 ng.mL-1 ml IL-6 could be detected through Au-NP modified capacitors with 1.85 pF 
capacitance change whereas the detection limit of the standard assay for IL-6 was 0.1 
ng.mL-1. The detailed comparison can be shown in Table 4-2. 
 
Table 4-2 Comparison of IL-6 detection for standard and Au-NP modified capacitive 
sensor platforms. 
 Standard assay Au-NP modification 
Concentration range 0.1-10 ng.mL-1 0.02-10 ng.mL-1 
Rmax for 10 ng.mL-1 IL-6 0.35 pF 2 pF 
Rmax for lowest IL-6 concentrations 0.33 pF 1.85 pF 
Detection limit 0.1 ng.mL-1 0.02 ng.mL-1 
Signal increase 1 fold ~6 fold 
 
The difference between the results of Au-NP modified and standard assays may be 
due to  (a) ability of Au-NPs to provide a more stable surface for antibody immobilization 
that retain their biological activities, (b) capture of more antigen due to more antibody on 
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Au-NPs (c) enhancement of orientational freedom for antigen binding on Au-NP 
modified sensor, (d) high surface to volume ratio and surface energy of Au-NPs, (e) 
ability of Au-NPs to decrease the distance between proteins and metal particles [101]. 
 
4.2 DEVELOPMENT OF MAGNETIC BEAD MODIFIED CAPACITIVE 
SENSOR PLATFORM 
In the previous section, Au-NP modified platform was described and the signal was 
increased via the enhancement of the surface for the binding of biological molecules. For 
this, the capacitive sensor platform was initially covered with a SAM layer and then 
modified with Au-NPs prior to the antibody immobilisation. Here, as an alternative 
approach, magnetic particles were used for signal amplification with different 
methodology. The beads were functionalized and injected to the sensor after antigen 
binding to improve the signal for the detection of trace marker concentrations which 
could not be detected without using magnetic bead modification.  
 
Magnetic beads used in biomedical applications present usually a core/shell structure 
such as iron oxide, surrounded by an outer layer of shell wall that consists of long-chain 
organic ligands or inorganic/organic polymers [102]. The attachment of bioactive ligands 
to the surface of the outer shell is the crucial point in bioapplications of magnetic beads. 
The main immobilization procedures of bioactive species using magnetic microbeads are 
summarized in Table 4-3. Magnetic microbeads can be used in three biosensing systems 
include affinity biosensors, enzymatic biosensors and bio-bar codes [103]. 
 
Capacitive immunosensors are designed through the immobilization of the specific 
antibody on the surface of the electrochemical transducer. The main problem affecting 
immunosensors is reproducible regeneration of the sensing surface. The need of renewal 
of the sensing surface arises from the affinity constants derived from the strong antigen-
antibody interaction. This renewal is a difficult task since the drastic procedures required 
alter immunoreagent bound to the surface of the transducer. This drawback makes 
immunosensors difficult to be integrated into automatic systems. An alternative approach 
avoiding regeneration consists of using disposable antibody-coated magnetic microbeads 
and building up in situ immunosensing surface by localizing the immunomagnetic beads 
on the electrode area with the aid of a magnet. Moreover, the use of immunomagnetic 
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beads is particularly evident in the detection of analytes contained in complex sample 
matrices that may exhibit either poor mass transport to immunosensor or physical 
blockage of immunosensor surface by non-specific adsorption. 
 
The immunomagnetic bead is pinched magnetically on the electrode surface, exposed 
to the enzymatic substrate and the electroactive product is detected electrochemically. 
This type of immunomagnetic electrochemical assay was applied for different analytes 
with different transducer/enzyme combinations as seen in Table 4-3.  
 
Table 4-3 Immunomagnetic electrochemical assays using different transducers and 
enzymatic labels. 
Analyte 
 
Transducer 
 
Enzyme 
 
Detection 
Limit 
 
Dynamic 
range 
 
Reference 
Rabbit 
IgG 
pH-ISFET urease 8nM 0 – 2.07μM [104] 
Rabbit IgG 
Graphite 
composite 
electrode 
HR 
Peroxidase 9x10
-6 μg.l-1 0 – 0.26μM [105] 
E. coli 
0157:H7 
Graphite ink 
electrode 
Alkaline 
Phosphatase 
4.7x103 
cells.ml-1 
0 –105  
cells.ml-1 
[106] 
2,4-D 
herbicide Nafion-SPE 
Alkaline 
phosphatase 0.01 μg.l
-1 0.01 - 
100μg.l-1 [103] 
Human 
IgG 
Carbon paste 
electrode 
HR 
Peroxidase 0.18 μg.ml-1 
0.51 – 30.17 
μg.ml-1 
[107] 
 
The magnetic beads aim at interacting with the target molecule through biological 
recognition, namely DNA/DNA complementary sequence (hybridization) or 
antigene/antibody interaction. It gives to the sandwich structure magnetic properties 
allowing its separation from unreacted material and medium. Immobilisation of the 
monoclonal antibody is achieved by reaction of glutaraldehyde with the primary amine at 
the surface of the particle and with free amine of the antibody. In the case of 
oligonucleotide target complement, the particle is modified with surface maleimido 
groups using succinimidyl 4-(p-maleimidophenyl) butyrate (SMPB)  or sulfosuccinimidyl 
4-N-maleimidomethyl cyclohexane-1-carboxylate (sulfo-SMCC) [108]. The 
oligonucleotide is then immobilised through thiol addition to the double bound of the 
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maleimido group. The average number of DNA strand per particles is 3 105. In the case of 
antibody immobilisation, the average number of immobilised molecules is 3500 (small) 
per MMB as estimated by optical density at 280 nm. Capping is accomplished with BSA 
or sulfo-NHS acetate [103]. Helali et al. developed an disposable immunomagnetic 
electrochemical sensor involving magnetic particles and employed the sensor for the 
detection of atrazine. The developed sensor was based on a magnetic monolayer of 
magnetic particles coated with streptavidin, formed on a gold electrode after application 
of a magnetic field. The experimental procedure was shown in Figure 4-8. The atrazine 
could be sensitively detected in the range of 10-600 ng.mL-1 and this study shows the 
promising usage of magnetic beads through impedimetric/capacitive sensors in 
biomedical applications with the aim of detection [109]. 
 
 
Figure 4-8 Experimental steps of atrazine detection using immunomagnetic 
electrochemical sensor. 
4.2.1 Behaviour of magnetic beads on the platform  
A stable dispersion of magnetic particles in a liquid medium plays critical role for the 
applications. Due to this, the characteristics of the particle surface have to be compatible 
with the medium used and the interaction between the particle and solvent must be strong 
to overcome Van der Waals attraction in the case of permanent magnetic moment of the 
particles. The behave of the magnetic particles suspended in a fluid and the magnetic 
moment can be described with two different mechanism. The first mechanism involves 
the bulk rotation of the particle within the fluid due to Brownian motion. This mechanism 
is usually used when the magnetic moments of the particles are fixed relative to the 
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crystal axes of the particles and the Brownian rotational diffusion time is defined by the 
equation 4-2. 
𝜏𝐵 = 4𝜋𝜂𝑟3𝑘𝑇     (Equation 4-1)  [110] 
 
Where r is the hydrodynamic radius of the particle, η is the dynamic viscosity of the fluid, 
k is Boltzmann’s constant and T is the absolute temperature. When a particle is 
unblocked, the magnetic moment vector rotates, but the particle remains stationary. The 
response of the magnetisation of a magnetic bead solution that includes spherical particles 
to an alternating magnetic field can be modelled by Debye theory to explain the dielectric 
dispersion in dipolar fluids. The fluid magnetisation is related to the applied magnetic 
field due to the finite magnetisation change with time. In a small applied field, the 
magnetisation is a linear function of the field; therefore, the magnetisation response to an 
alternating field can be defined depending on the complex magnetic susceptibility.  
     When biological macromolecules bind to the particles, the hydrodynamic radius of it 
increases and this increase leads to decrease in the frequency. The higher the increase in 
the hydrodnamic radius, the higher will be the frequency shift [110]. Due to the big 
hydrodnamic radius of our magnetic beads, a frequency shift was expected when 
compared with our normal frequency range for standart bioassays and the obtained results 
of magnetic bead investigations supported all of these hypothesis. 
As a part of PhD thesis, magnetic beads have been used to develop capacitive sensor 
platform to obtain more stabile and sensitive surface with higher specificity for bioassays 
as an alternative to Au-NP modified sensor. The purchased MBs have an iron core with 
three positive charge and capsulated with glycydyle ether that has hydrophilic nature. The 
coat seals the iron oxide inside the beads, and the surface is activated with primary amino 
funtionality on a short hydrophilic linkers. The MBs have neutral net charge due to the 
hydrophilic coat; however, the charge distribution on the sensor are changed due to the 
positive charge of the iron core since the positively charge layer of the bead induce the 
negative charge on the sensor layer due to the electric field. More charge increases the 
electric field and polarization, thus, the measured capacitance will increase. This can be 
theoretically explained with the equation 4-3 where the increase dipole moment (m) leads 
to decrease in impedance (Z); moreover, the capacitance (C) shows an increase in this 
case due to the reverse relationship between Z and C.  
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𝑍(𝜔) = 𝑍(𝑜){1 −𝑚 �1 − 1
1+(𝑗𝜔𝜏)�}   Equation 4-2 
 
Charge distrubition is the most crucial issue in capacitive sensor platform and it may 
be affected by electrical permittivity of the medium, nature of the biological molecule, 
dipole-dipole interaction between molecules, pH and the temperature of the used media in 
the assays. Since the charge distribution plays a direct role on capacitor, the sensor 
surface must be uniform and the clusturing of the particles must be counteracted. The 
clustered particles may lead to short-circuiting; therefore, decrease in capacitance and/or 
collapsing of the capacitors on the sensor platform. When all of these issues are 
considered, it is clear that the concentration, manupulation, application type of MBs are 
very important in our research. For an instance, high concentration of MBs cause the 
clusturing and short-circuiting or specific usage of the MBs is critical in bioassays. Bare-
MBs were previously investigated on our IDE-based capacitive sensor to determine the 
effect of MBs on capacitance and the appropriate concentration of the MBs without 
observing any clustered particles on the surface.  
 
Figure 4-9 Schematic representation of gold interdigitated fingers of an IDE. 
 
The sensor surface was calculated using the dimension of the gold area on the sensor 
(Figure 4-9). Total gold area was calculated as 918.400 µm and this result was divided to 
one magnetic bead area (a MB has 2.8 µm radius) to find the number of needed MB to 
coat all surface. It was found that 125.000 MBs were necessary to coat all surface (100% 
coverage) and the MB concentrations were prepared as a serie. Prior to the preparation of 
MB concentrations, 25% and 50% MB were examined on two IDE electrodes and the 
40 µm thickness 40 µm x800 µm
24 gold fingers
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surfaces were checked under the microscop to observe whether clusters occur or not. It 
was found that 50% MB caused an apparent agglomeration; therefore maximum 
concentration of MBs for preliminary testing was choosen as 25%. The tested 
concentrations  were 25%, 20%, 17%, 12%, 10%, 6%, 5%, 3% and 0% (only PBS buffer 
that used for the dilution of MBs). The data analysis showed that higher concentration of 
MBs leads to decrease in capacitance and the evaluated capacitance was lower than the 
negative control except for 3% and 5%. The tested MB concentrations were measured by 
Network analyzer in the frequency range of 50 MHz-4 GHz as seen in Figure 4-10a. It 
was observed that capacitive response coming from MB application has shown a 
stabilisation after 1000 MHz and a clear response obtained between 500-1000 MHz 
(Figure 4-10b). 
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Figure 4-10 Bare-MB measurements according to the tested concentrations of MBs by 
Network Analyzer in a wide (50MHz-4 GHz) and zoomed (600-1000 MHz) frequency 
ranges. 
 
Moreover, when the incubation time was extended, a weak agglomeration was also 
observed on IDE electrodes coated with 20% and 25% MBs. These findings indicate that 
the appropriate concentration of MBs for our sensor platform should be 5% or lower to 
obtain a uniform and stabile surface without any problem on charge distribution, thus on 
capacitance. After obtaining these results from bare-MB study, 1% MB concentraiton was 
chosen to use in bioassays and this MB concentration was also tested on SAM coated 
sensor surface without any modification (no biological molecule or coating with 
secondary antibody). 1% MB was measured in the same frequency range with bare-MB 
study and similar results were recorded. It was shown that MB usage led to a shift in 
frequency up to 1000 MHz while our normal range for biological assays without particles 
a) b) 
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is between 600-900 MHz. Moreover, 1% MB concentration gave the higher capacitance 
change when compared with 3% MB tested in previous experiments and this was the 
expected output since the decrease concentration of MB leads to the increase in the 
capacitance. 3% and 1% MBs produced ~3 pF and ~3.5 pF capacitance, respectively. 
Figure 4-11 shows the result of 1% MB application on the SAM coated sensor surface 
and in a broad and zoomed frequency range. The capacitive response of 1% MB on SAM 
layer was scanned in the frequency range of 50 MHz- 4 GHz and a stabilization on the 
capacitance was observed at 1 GHz frequency point as in Figure 4-10. The results 
indicated that there is no change on the response after 1 GHz while working with 
magnetic beads. Due to this, the frequency range was determined up to 1 GHz for the 
assays. 
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Figure 4-11 Capacitance measurements of 1%MB on SAM-coated sensor surface in a 
broad (a) and particular frequency ranges (b). 
 
After the optimization of frequency range for MB application and the determination of 
MBs behavior on the capacitive sensor platform, real bioassays were conducted using 
CRP antibody-antigen pair in the frequency range of 50 MHz-1 GHz since this marker 
was previously investigated and succesfully detected using standard assay approach 
through capacitive sensor platform in our research group. After the testing of the MB-
modified sensor with CRP, the methodology was transferred into lung cancer biomarkers 
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for the detection. This section will continue with methodology of MB-modified platform 
in bioassays. 
4.2.2 Methodology 
4.2.2.1 The protocol of the applied bioassay using magnetic beads: 
1) Self assembled monolayer was formed on the capacitive sensor surface using 10 
mM thiourea prepared in analytical grade ethanol.  Overnight incubation was 
applied under dark conditions at ambient temperature. 
2) The sensor surface was activated with the mixture of EDC and NHS in 1:1 volume 
ratio using 0.1 M EDC and 0.05 M NHS during 3 hours incubation. 
3) 25 µg.mL-1 antibody was immobilized to the activated sensor surface for the 
antibody immobilization and the wafer was incubated for 2 hours. 
4) To cap the antibody-free areas of the sensor surface,  ethanolamine was applied to 
the sensor for 1 hour. 
5) Different concentrations (10-500 pg.mL-1) of CRP protein were prepared within 
PBS buffer and antigen was injected to the sensor for 2 hour incubation. 
6) Sandwich assay was applied using secondary antibody immobilized-magnetic 
beads.  
4.2.2.2 Preparation of secondary antibody immobilized-magnetic beads 
Dynabeads M-270 Epoxy are uniform beads composed of crosslinked polystyrene 
with magnetic material precipitated in pores evenly distributed throughout the particles. 
The beads are further coated with glycidyl ether (epoxy) functional groups which seals 
the iron oxide inside the beads. The epoxy groups allow for binding of biological 
molecules such as proteins, peptides or other ligands, with covalent bond formation at 
neutral pH. The glycidyl ether coat of the beads has hydrophilic  nature.  The beads 
should be washed prior to coating with secondary antibody will be used in sandwich 
assay. The following steps are performed before the use of the beads in bioassay: 
 
1) 0.1 M PBS buffer (pH 7.4) was added to the tube that includes the magnetic 
beads. 
2) The tube was vortexed for 30 seconds and incubated with mixing for 10 minutes. 
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3) The tube was placed on a magnet for 2 minutes and carefully pipetted off the 
supernatant and the beads are left undisturbed. 
4) The test tube was removed from the magnet and the beads are carefully 
resuspended in the same volume of the buffer. Vortex was used to mix the tube 
properly. 
5) Third step was applied again. 
6) The washed beads were resuspended in the same buffer. 
7) Calculated concentration of the antibody (5 µg.mL-1, 3 µg.mL-1  and 1 µg.mL-1) 
was added to the bead suspension. The tube was vortexed to ensure good mixing 
prior to the addition of the calculated amonium sulfate-stock solution. 
8) The test tubes include different concentrations of the antibody was incubated for 
16-24 hours to make the covalent coupling faster and more efficient. 
9) After incubation period, the tube was placed on the magnet for 4 minutes for 
magnetic seperation and the supernatant was carefully removed. 
10) The coated beads were washed for 4 times with PBS buffer.  BSA was added to 
the last solution for blocking.  
11) The prepared magnetic beads coated with secondary antibody was used in the 6. 
step of the bioassay in the current investigation. The principle of the applied 
bioassay is shown in Figure 4-12. 
 
 
Figure 4-12 The principle of the applied bioassay using magnetic particles. (Adapted). 
[111]  
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4.2.3 Results 
Magnetic beads have much bigger size when compared with proteins. Due to this, a 
large number of antibody bind to only one magnetic beads and low concentration of 
magnetic beads are required in the current methodology that provides cheaper and easily 
applicable approach. For optimization of the assay parameters with magnetic beads, a 
well-known surface chemistry was applied using thiourea that has two amine group to 
catch more activation material when compared with other thiol molecules used in our 
previous works. 1% magnetic bead concentration was preferred to use in this study 
according to the preliminary testing of different bead concentrations. This concentration 
can be further decreased according to the concentration of the target marker or the size of 
the target antigen and antibody. When the investigated marker concentration is selected in 
lower levels such as ng.mL-1 or pg.mL-1, the available marker number is more limited on 
the sensor surface that means the required secondary antibody or magnetic bead 
concentration will decrease. In the case of smaller size protein markers or antibody, the 
magnetic bead concentration should also be decreased even the secondary antibody 
concentration is increased to increase the probability of secondary antibody coated MB 
binding to the antigen injected sensor surface. 
Here, two different secondary antibody concentrations (3 µg.mL-1 and 5 µg.mL-1) 
were used to coat 1% magnetic beads and the solutions were applied for the antigen 
concentrations as two main paralels. (One paralel includes the detection range of 10-500 
pg.mL-1 antigen and 3 µg.mL-1 secondary antibody coated magnetic beads application 
whereas the other includes the same antigen series with 5 µg.mL-1 secondary antibody 
coated magnetic beads.) Since 3 µg.mL-1 secondary antibody concentration gave better 
results, this concentration was chosen to use in bioassays for the modification of MBs. 
4.2.3.1 Antigen binding on the surface 
Here, CRP-anti-CRP pair was tested using magnetic bead-modified sensor platform. 
CRP has 224 aminoacid lengt and the size of it has been determined by Matrix-assisted 
laser desorption/ionization (MALDI) technique as 23026 Da. CRP exhibits several 
functions associated with host defense; for instances,  it promotes agglutination, bacterial 
capsular swelling, phagocytosis and complement fixation through its calcium-dependent 
binding to phosphorylcholine. The protein can interact with DNA and histones and may 
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scavenge nuclear material released from damaged circulating cells. Due to its broad range 
effects in the cell, it has crucial roles in cancer, cardiovascular system diseases and some 
other complications.  
To determine the efficiency of our capacitive sensor with magnetic bead modification, 
a detection range of 10-500 pg.mL-1 was selected as the marker concentration. The CRP 
protein could be clearly detected in the range of 10-500 pg.mL-1 and the negative control 
showed a background signal at ~0.17 pF level. The significant and stabile capacitance 
change was observed between 600-900 MHz. Figure 4-13 and Figure 4-14 shows the 
antigen detection responses in the whole and a constant frequency point, respectively. 
Linear regression analysis was performed at 800 MHz and R2 value was calculated as 
0,974.  
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Figure 4-13 CRP antigen detection in the concentration range of 0-500 pg.mL-1 at all 
frequency range. 
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Figure 4-14 Capacitive detection of CRP antigen in the concentration range of 0-500 
pg.mL-1 at a constant frequency. 
 
4.2.3.2 Modified MB application on the surface 
After the measurements of antigen binding, MB application was conducted using 
secondary antibody-coated magnetic particles. The prepared MB solution was applied to 
each sensor by a pipette using 3 µl volume per capacitor. Three capacitors were employed 
to obtain the negative control. For the control, the sensor was immobilized with anti-CRP 
antibody and PBS buffer was then injected to the sensor surface instead of the target 
antigen (CRP). After antigen binding step of the assay, these electrodes were treated with 
secondary antibody coated-MBs as in the positive samples. 3 h incubation was performed 
for MB application to all capacitors. Each electrode was then washed with a pipette using 
PBS and dH2O for several times to prevent from outspreading. The sensor was then dried 
prior to take measurements by Network Analyzer.  
The change in capacitance due to the MB application was calculated for each antigen 
bound electrode and standard deviations were obtained from each 3 electrodes that were 
treated with same antigen concentration at the antigen binding step. The capacitance 
change was calculated as the normalized capacitance according to the equation 4-3. 
Normalized ∆C = CMB−CAntigen
CAntigen
   Equation 4-3 
 
Figure 4-15 shows capacitance change after MB application on the surface and the 
obtained responses represent an increase on the capacitance change depending on the 
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incerease antigen concentration on the surface. A clear signal difference was observed 
due to the MB usage on the platform. Lowest antigen concentration (10 pg.mL-1 CRP) 
gave ~0.17 pF capacitance change at antigen binding stage, whereas the response on this 
surface increased to ~2.1 pF after secondary antibody-coated MB application. 
 
Figure 4-15 Capacitance change after secondary antibody-coated MB application on the 
antigen bound surfaces in all frequency range. 
 
For the frequency range, the optimal range was found between 600-1000 MHz 
although the best output was obtained in the range of 800-900 MHz as seen in Figure 
4-16a. Moreover, specificity of the assay was determined using a negative control; thus, 
MB application on the lowest antigen concentration and the antigen-free control were 
compared. MBs on the control surface produced ~0.25 pF capacitance change while it 
was ~2.5 pF on the antigen bound surface that has lowest concentration (10 pg.mL-1) as 
shown in Figure 4-16b. 
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Figure 4-16 Capacitance change after secondary antibody-coated MB application on the 
antigen bound surfaces in the frequency range of 600-1000 MHz (a) and the difference 
between the control surface and the lowest antigen bound surface after MB application 
(b). 
 
The development of MB-modified capacitive sensor platform indicated an alternative 
methodology for the detection of cancer biomarkers, especially for small size or low 
threshold level biomarkers. The bioassays conducted using CRP antigen-antibody pair 
with MB-application gave expected results and the platform was optimized to work with 
magnetic particles for the detection of disease markers. The MB-modified platform was 
also used for multiple marker detection to provide an alternative quantification approach 
to the Au-NP modified sensor platform for precise disease diagnostics. 
4.3 MULTIPLE MARKER ASSAY FOR PRECISE DISEASE DETECTION 
Label-free biosensors can detect disease markers to provide point-of-care diagnosis 
that is low-cost, rapid, specific and sensitive [112-125]. Biomarkers have emerged as 
potentially important diagnostic tools for cancer and many other diseases. Continuing 
discoveries of such biomarkers and their aggregation into molecular signatures suggests 
that multiple biomarkers will be necessary to precisely define disease states. Thus, 
parallel detection of biomarker arrays is essential for translation from benchtop discovery 
to clinical validation. Such a technique would enable rapid, point-of-care (POC) 
applications requiring immediate diagnosis from a physiological sample. Critically, such 
a system must also be capable of detecting very low levels of aberrant genes and proteins, 
as many biomarkers are present at minute concentrations during early disease phases 
a) 
b) 
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[115-118]. Due to this, multiple marker detection was investigated for lung cancer 
markers through employing nanoparticle modified electrochemical-based capacitive 
biosensors and the multiple detection of lung cancer protein markers (CEA, EGFR and 
CA 15-3) was investigated for the first time (Figure 4-17).  
 
Figure 4-17 Schematic representation of capacitive biosensor chips (a) and bioassays 
applied with the particle modifications (b). (b part of the figure was adapted). [111] 
 
4.3.1 Materials and Reagents 
Monoclonal antibodies and purified antigens for CEA and CA15-3 were purchased 
from Fitzgerald (USA). Sheep monoclonal antibody to human epidermal growth factor 
receptor (anti-hEGFR) and human epidermal growth factor receptor (hEGFR) were 
bought from Sigma Aldrich (USA). All other reagents and solvents of analytical grade 
were purchased from the companies as mentioned in previous sections of the thesis. 
4.3.2 Antibody immobilization (anti-CEA, anti-hEGFR and anti-CA15-3) 
Antibody immobilization on Au-NP modified and magnetic particle modified sensor 
platforms was carried out as described in section 3.2.1.2 and 3.3.3, respectively. The GID 
electrode surfaces of capacitors were immobilized by incubating 2.5 µL of 25 µg.mL-1 
anti-CEA, anti-hEGFR and anti-CA15-3 antibodies in PBS buffer for 1 h. The sensor 
Blank controls
BSA controls
CEA samples
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wafer was then washed with PBS and dried prior to the blocking step with ethanolamine. 
The non-reacted groups on the sensor surface were blocked by adding 5 µL of 100 mM 
ethanolamine on each GID electrode and incubated for 2 h. The sensors was then rinsed 
with PBS and sterile dH2O, and dried with nitrogen gun prior to the measurements for 
antibody immobilization using a Network Analyzer. The analyzer was calibrated and 
triplicate measurements were then taken for each GID electrode for error analysis.  
4.3.3 Detection of multiple cancer markers 
A series of antigen concentrations in the range of 0-1 ng.mL-1 were initially prepared 
in PBS buffer on ice. The capacitors were then incubated for 2 h with different antigen 
concentrations in 2.5 µL volume for each biomarker. The capacitive measurements were 
taken before and after the antigen treatment. The capacitance was measured with (a) 
blank capacitor, (b) capacitor after SAM formation, (c) after Au-NP modification, (d) 
after antibody immobilization and compared the results with (e) capturing of different 
concentrations of antigens on the antibody immobilized capacitors. In the case of 
magnetic particle modified capacitive platform, secondary antibody-coated magnetic 
beads were applied on the antigen bound surface and the signal was measured instead of 
the measurement c. Network analyzer was calibrated using SOLT (short-open-load-
through) method prior to the measurements. Capacitance change was calculated from the 
measurements of the sample capacitance and 3 individual electrodes were used for each 
antigen concentration to understand the repeatability and reliability of the assays. 
Capacitance change was calculated from the data measurements in the effective frequency 
range of 500-1000 MHz for plotting under standard assay conditions. Negative control 
assays were also performed using the buffer solution and BSA protein to check the 
specificity of the assays. Averages values of ∆C obtained from triplicate experiments were 
plotted and the standard deviations were calculated that were shown as errors. 
4.3.4 Results and Discussion 
In this study, multiple markers of lung cancer were investigated using nanoparticle 
modified capacitive sensor platform for the first time. With this aim, three target protein 
markers (CEA, hEGFR and CA15-3) were selected due to their presence at elevated 
levels in human blood for the cancer cases and worked employing two different 
methodology of nanoparticle modification.  
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Au-NP modification was carried out after SAM formation with thiourea for signal 
enhancement via the increase of surface for the biological molecules. After the 
modification of the sensor surface with Au-NP during 8 h incubation, antibody 
immobilization was performed using three different target antibodies. Antigen binding 
step of the bioassay was then applied in the concentration range of 0-1 ng.mL-1 for CEA 
and hEGFR while 0-100 U.mL-1 for   CA15-3. BSA was used as negative control to 
determine the specificity of the assays.  
 
In the case of modification with magnetic particles, antibody immobilization and 
antigen binding steps of the experiments were conducted and the signal was then 
enhanced applying secondary antibody coated magnetic beads on the antigen bound 
surfaces. Same concentrations with Au-NP modified sensor were used here and the 
results were compared as capacitance change according to the target marker and the 
modification type with nanoparticles. The capacitance change of Au-NP modified sensors 
were calculated for CEA, hEGFR and CA15-3 cancer markers and successful detection 
was achieved in the concentration range from 5 pg.mL-1 to 1 ng.mL-1 for each marker. 
The specificity of the assays were checked using a non-specific protein (10 ng.mL-1 BSA) 
and a clear difference was observed between the lowest concentration of the antigen and 
the controls. PBS buffer (0 pg.mL-1 CEA, EGFR or CA15-3) was also tested as negative 
control on the antibody immobilized sensor surfaces (anti-CEA, anti-hEGFR and anti-
CA15-3) to measure the baseline response of the solution used for the preparation of the 
samples. The capacitive responses of the sensors were plotted in the optimal frequency 
range for protein markers (Figure 4-18). 
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Figure 4-18 Capacitive detection of CEA, hEGFR and CA15-3 cancer markers with Au-
NP modified capacitive sensor in the frequency range of 500-900 MHz. CEA and hEGFR 
detection in the concentration range of 5-1000 pg.mL-1 (a and b). CA15-3 marker 
detection in the concentration range from 1 U.mL-1  to 100 U.mL-1 (c). 
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Capacitance responses of the marker at a constant frequency were also compared in 
the concentration range of 5-1000 pg.mL-1 for CEA and hEGFR, and 1-100 U.mL-1  for 
CA15-3 proteins as shown in Figure 4-19 and the regression analysis was also performed 
for each marker and R2 values were calculated as 0.99, 0.94 and 0.98 respectively (Figure 
4-20). The results of CA15-3 detection were plotted separately due to the difference 
between concentration types. The normal range of CA15-3 marker in human blood is 50 
U.mL-1 and the increased level of the marker plays a role as cancer indicator. The marker 
has not been tested with sensor technologies whereas ELISA tests have been conducted 
for clinical analysis and disease diagnostics. Moreover, this marker has been investigated 
as U.mL-1 instead of molar concentration due to its enzymatic behaviour and the detection 
limits of commercially available ELISA kits change between 5-10 U.mL-1. The 
concentration of samples for CA15-3 marker was prepared according to the threshold 
level of the marker in human blood and ELISA tests and the concentration range of 1-100 
U.mL-1 was successfully detected as shown in Figure 4-20. 
 
 
Figure 4-19 Multiple marker detection at a constant frequency (800 MHz) with Au-NP 
modified sensor platform. The concentration range of CEA and EGFR is 5-1000 pg.mL-1 
while it is 1-100 U.mL-1 for CA15-3 protein marker. 
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Figure 4-20 Regression analysis of the bioassays conducted with Au-NP modified sensor 
platform at a constant frequency. The specificity of the assays was tested using PBS 
buffer (0 pg.mL-1 marker) and a non-specific protein (10 ng.mL-1 BSA). 
 
 
 
The results of CEA and EGFR detection according to the antigen concentration were 
found very similar while the obtained signal was quite different when compared with 
CA15-3 protein. The similarity of the results for CEA and EGFR may depend on the 
molecular weight of the markers that are very close to each other and the same 
concentration level of the prepared samples. The results of CA15-3 tests show difference 
due to the concentration type (U.mL-1 instead of pg.mL-1) when compared with the other 
markers and the sample concentrations of CA15-3 were in trace amount in this study. The 
marker could be successfully detected at 1 U.mL-1 concentration using Au-NP modified 
sensor platform which is much lower than the threshold level and ELISA kits.  
 
Moreover, the efficiency of Au-NP modified capacitive sensor platform can also be 
compared with the previous hEGFR results in which a standard capacitive sensor was 
employed. For example, 1 ng.mL-1 concentration of hEGFR gave ~0.3 pF capacitance 
change with non-modified sensor whereas the same amount of the antigen produced ~1.6 
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pF capacitance change with Au-NP modified sensor platform and the modification led to 
detect much lower concentration such as 5 pg.mL-1 at high specificity.  
 
Multiple markers of lung cancer for precise disease diagnosis were also investigated 
using magnetic bead modification. Here, the modification was applied after the antigen 
treatment on the sensing surface to enhance the signal. For this, the magnetic beads were 
initially functionalized with secondary antibodies (anti-CEA, anti-hEGFR or anti-CA15-
3) and the solutions were then applied to the sensor after antigen binding during 2 h 
incubation at room temperature. The ∆C was calculated for antigen binding step at the 
selected concentration range. A clear capacitance change was observed depending on the 
marker concentration although the lowest concentrations of the markers gave little 
difference when compared with the negative protein control (10 ng.mL-1 BSA) as shown 
in Figure 4-21.  
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Figure 4-21 Capacitance change on the sensor due to the antigen binding at the effective 
frequency range prior to the magnetic bead modification. CEA and hEGFR marker 
detection in the concentration range of 5-1000 pg.mL-1 (a, b). CA15-3 detection in the 
concentration range of 1-100 U.mL-1 (c).  
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When we compared the antigen binding results of these assays with Au-NP sensor 
platform (the modification was carried out after SAM formation and the surface was 
enhanced for the binding of biological molecules), it was observed that all sample 
concentrations were clearly detected with a higher signal on Au-NP modified sensor 
platform whereas the lowest sample concentrations gave a weak response in these 
bioassays that cannot be meaningful in our sensor platform. Moreover, the highest 
concentrations of the markers produced much more capacitance change in the case of Au-
NP modification. For instance, 1 ng.mL-1 CEA gave ~1.6 pF ∆C with Au-NP modification 
while it led only 0.5 pF ∆C prior to the magnetic bead application to the sensor in these 
bioassays. 
 
After the antigen detection stage of the bioassays, the sensor surface was modified 
with secondary antibody coated magnetic particles to enhance the signal and the results 
were evaluated as ∆C for each marker. The difference between the negative controls (PBS 
buffer and BSA protein) and the sample concentrations showed a change in capacitance 
drastically as seen in Figure 4-22. Moreover, the magnetic bead modification increases 
the signal ~5 fold and it led to a meaningful detection for the lower concentrations of the 
markers when compared with the controls. A significant signal increase was observed for 
the 5 pg.mL-1, 1 U.mL-1 and 5 U.mL-1 concentrations of the markers against the negative 
control in the case of magnetic bead modification; therefore, this output indicates the 
importance of the particle usage in our platform for reliable detection of the cancer 
markers. The ∆C results of magnetic bead modification showed that there was trace 
amount of the marker bound on the antibody immobilized sensor surface although it 
could not give an observable change in capacitance prior to the particle modification. The 
magnetic particle modification increased the signal for 5 pg.mL-1 of CEA from ~0.05 pF 
to ~1.6 pF whereas the signal was change from ~0.05 to ~0.07 pF for the non-specific 
protein control. 
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Figure 4-22 Signal enhancement with magnetic particles for the detection of CEA marker 
in the concentration range of 5-1000 pg.mL-1 at the effective frequency range. 
Comparison of the sample responses with the negative controls after magnetic bead 
application (a). The results of constant magnetic bead solution application on the different 
CEA concentrations in the concentration range of 5-1000 pg.mL-1 (b). Specificity test of 
the bioassays using the lowest amount of CEA sample and the negative controls (c). 
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As a part of multiple marker tests using magnetic bead modification in the capacitive 
sensor, the signal enhancement assay was also conducted for hEGFR and CA15-3 bound 
surfaces. The similar results were obtained for these markers and the particle application 
on all investigated antigen concentrations led to a significant signal increase whereas a 
difference was not observed for the control surfaces as seen in Figure 4-23.  
 
 
Figure 4-23 Signal enhancement with magnetic bead modification on the capacitive 
sensor platform for hEGFR and CA15-3 cancer markers at the effective frequency range. 
Capacitance change due to the magnetic bead application after antigen binding step of 
hEGFR bioassay with/out the negative controls (a, b). Capacitance change due to the 
magnetic bead application after antigen binding step of CA15-3 bioassay with/out the 
negative controls (c, d).  
 
The results obtained during this PhD thesis have provided alternative approaches for 
cancer detection and quantification using biomarkers. The developed and improved 
methodologies/sensors can also be applied for the other diseases that have biomarkers in 
human body. A comparison of all sensor platforms used throughout the PhD process can 
be seen in Table 4-4. 
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Table 4-4 Comparison of all investigated sensor platforms in this PhD thesis. 
 
 QCM/SPR 
sensors Capacitive Sensor 
Capacitive sensor 
with Au-NP 
modification 
Capacitive sensor 
with MB 
modification 
Concentration 
range 3-400 ng/ml 0.5-256 ng/ml 5 pg/ml-1 ng/ml 5 pg/ml-1 ng/ml 
Detection limit 3 ng/ml 0.5 ng/ml 
 
5 pg/ml 
 
5 pg/ml 
Signal 
amplification as 
detection limit 
1 fold 6 fold 600 fold 600 fold 
Signal 
amplification as 
∆C 
- 1 fold ~5 fold ~5 fold 
Specificity High (~0) High (~under zero) Good ( ~0,2 pF) High ( ~0) 
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CHAPTER 5 
 
 
5 SUMMARY, CONCLUSION AND FUTURE PROSPECTS 
In this thesis, an electrochemical based, cost effective, highly sensitive capacitive 
biosensor was developed using different nanoparticles to promote lung cancer detection 
for the first time. SPR and QCM-based sensors were employed to develop the bioassays 
and the surface chemistries for the detection of biological molecules [56, 126]. The 
successful achievements of these research works were transferred into an electrochemical 
based-biosensor to decrease the cost, time and need to special skills on the usage of these 
sensors and increase the sensitivity, reliability of the assays for the quantification of the 
biological markers, especially small-sized and trace threshold level markers, with the aim 
of disease detection. The optimized sensor methods were conducted in the capacitive 
sensor using standard methodologies and the detection limits of the other sensors for the 
biomarker quantification were decreased efficiently without any signal amplification 
methodology. However, the signal enhancement plays crucial role in the quantification 
through biosensors due to the need for sensitive and reliable detection of some markers 
that have too low levels as the cancer indicators. For an instance, disease levels of many 
biomarkers are at ng.mL-1 ranges such as CEA [56], hEGFR [79], PSA [68] while some 
others have the level at pg.mL-1 ranges such as IL-6 [127].  
 
Moreover, the binding affinity between the biosensing molecule and the target is one 
of the most crucial parameter in biosensor assays. In this study, kinetic data analysis was 
performed using 1:1 Langmuir binding model and the affinity between antibodies and the 
target antigens were increased when the bioassays were optimized. For an instance, the 
standard and the optimized assays were compared in SPR sensor and Rmax were increase 
from 215 RU to 734 RU. The dissociation constant was also decreased from 8.8 x 10-9 M 
to 3.04 x 10-11 M in the case of optimization and this indicated the increment of affinity 
between the target pairs. 
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Last decades are the heyday of biosensor technology; however, there have been still 
some gaps to fulfil and important problems to solve such as cross-reactivity between 
biological molecules and sensitivity/specificity/accuracy of the sensor/sensor surface 
chemistry, etc. Another important issue about cancer detection by biomarkers is the 
availability of the antibody or probes with an excellent specificity against the target 
protein or genetic marker. Due to this fact, there is a need to use bioinformatics tools and 
compare the sequences of the selected human proteins and genes with many species such 
as goat, monkey, mouse and rabbit. The achievement of this kind of research can be 
evaluated to produce biosensing molecules under laboratory conditions. The successful 
results of the production can eliminate the need for commercial antibody or probes that 
are quite expensive and show an unacceptable specificity against targeted biomarkers. 
The production strategies may also provide fundamental methodologies and approaches 
for both the commercial markets and research facilities. Moreover, real patient samples 
and human serum include various biological molecules beside the target analyte; thus, 
make the detection difficult due to the non-specific responses and require the signal 
amplification using appropriate modification.  
 
5.1 Novelty and Quality of the Work 
Here, both Au-NPs and MBs were successfully implemented to the non-faradaic 
interdigitated capacitive sensor for the first time and 600-fold increment was achieved as 
the detection limit for the tests of lung cancer biomarkers. Multiple marker detection for 
the precise cancer definition employing the capacitive sensing platform was the other 
novelty of the research. The improved methodologies and the obtained results provide a 
very prospective alternative approach for the early diagnosis of the cancer cases without 
an invasive and painful tool such as biopsy. The achievements of the study can also be 
compared with the other non-invasive methods including SPR, QCM and capacitive 
sensors in the literature. Table 5-1 summarizes the different sensing platforms depending 
on the detection methods and the sensitivity; indicates the efficiency and priority of our 
research works. When we compared our work within itself, it is clear that the particle-
modified sensor platforms have provided a significant superiority over the other sensors 
(SPR and QCM) and non-modified capacitive sensor platform. (The asterisk shows the 
samples prepared in the diluted serum.) 
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Table 5-1 Comparison of different sensor platforms for the marker detection with each 
other and our results in this thesis. 
 
Method Detectable 
range 
Sensitivity Signal 
enhancement 
methodology 
Labelling Reference 
QCM 4.7-5000 
ng.ml-1 
4.7 ng.ml-1 - - [68] 
QCM 2.3-150 ng.ml-1 2.3 ng.ml-1 yes yes [68] 
QCM 0.29-150 
ng.ml-1 
0.29 ng.ml-1 yes - [68] 
QCM 0.001-100 µg. 
dl-1 
0.001 µg. dl-1 yes yes [128] 
SPR 10.2-18.1 
ng.ml-1 
10.2 ng.ml-1 yes yes [129] 
SPR 20.7-47.5 
ng.ml-1 
20.7 ng.ml-1 - - [129] 
Capacitance 
biochip 
10-1000 times 
diluted human 
serum 
2.43 µg.ml - - [54] 
Capacitive 
sensor 
1-75 ng.ml-1 1 ng.ml-1 - - [130] 
Capacitive 
sensor 
0.05-75 ng.ml-1 0.05 ng.ml-1 yes - [130] 
SPR in this 
work 
3-400 ng.ml-1 3 ng.ml-1 - yes [56] 
QCM in this 
work 
3-400 ng.ml-1 6 ng.ml-1 - yes [56] 
Capacitive 
sensor in this 
work 
0.5-256 ng.ml-1 0.5 ng.ml-1 - -  
Au-NP 
modified 
capacitive 
sensor in this 
work 
5-1000 pg.ml-1 5 pg.ml-1 yes -  
MB modified 
capacitive 
sensor in this 
work 
5-1000 pg.ml-1 5 pg.ml-1 yes -  
 
5.2 Future Prospects 
This work has shown that biosensor technology provides the alternative and reliable 
detection/quantification approaches using biomarkers for the early detection of lung 
cancer that has the highest mortality rate in all cancer types due to the short survival time 
and quick invasion of the malign tumors. The markers of the disease can be used to define 
the cancer cases with a non-invasive technology; however, only one marker may not be 
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enough for the precise detection. Due to this, as one of the most important aspects of this 
PhD thesis, multiple marker quantification has crucial role and increases the reliability of 
the biosensors in disease detection. The normal ranges of many biomarkers are at ng.mL-1 
and it is possible to detect these amounts using appropriate surface chemistries/ bioassays/ 
biosensors. However, there are some challenges about the determination of the disease 
markers through biosensors including (a) affinity between the sensing molecule 
(antibody, probe, aptamer) and the target (protein or gene marker), (b) small size of the 
target (a few kD, 24 kD), (c) trace amount of the marker in human body in disease cases, 
(d) possibility of high non-specific binding in the case of serum or real patient samples, 
(e) the effect of the microfludics systems or the open system of the sensors during the 
quantification/ measurement processes. All of these issues will form the subjects of 
subsequent research projects and challenges. 
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